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INTRODUCTION
Continuous intravenous infusion is recognised1 as a superior mode of drug 
administration  not  only  to  by  pass  hepatic  “first  pass”  metabolism,  but  also  to 
maintain constant drug level in the body. This provides direct entry of drug into the 
systemic circulation but entails certain risks.
Recently,  the benefits  of  I.V.  drug infusion  can  be duplicated  without  its 
hazards  by  using  skin  as  the  port  of  drug  administration  to  provide  continuous 
transversal drug infusion into the systemic circulation.
Topical administration is employed to deliver a drug immediately at the point 
of application, so enough drugs is absorbed into the systemic circulation to cause 
therapeutic  effects.  To  provide  continuous  drug  infusion  through  an  intact  skin, 
several topical formulations are used one of this is “Gels”. 
Gels mainly used for the purpose of topical dosage form especially which is 
to deliver drug across a localized area of the skin.
The demanding expectations of topical include:
1. Formulation of gel should have both physical and chemical stability   
2. Formulation that have one (or) more components are non-sensitizing, non-
    irritating.
3. Formulation should have acceptability of the patient.
4. Formulation must have ability to release therapeutic levels of drugs and 
various  
    factors influence the absorption through the skin.
SKIN CHARACTERISTICS2, 3
             The purpose of topical dosage form is to conveniently deliver drugs across a 
localized  area  of  the  skin.  Medications  are  applied  to  the  skin  in  the  form  of 
ointments,  creams,  gels  etc.  The absorption  of  substances  from outside  the  skin, 
including entrances into the blood stream is referred to as percutaneous absorption. It 
is necessary to understand the skin characteristics to develop an ideal topical dosage 
form.
SKIN
The skin is an organ because it consists of tissues structurally joined together 
to perform specific activities. It is one of the larger organs of the body in terms of 
surface area. For the average adult, the skin occupies a surface area of approximately 
2 sq.m (3000 sq.inches)
It is a common site of administration for dermatological drugs to achieve a 
localized pharmacological action. Here, the drug molecules diffuse to a target in the 
skin  to  produce  its  action  before  it  is  distributed  to  the  blood  circulation  for 
elimination.
The skin also serves as a port of administration for a number of systemically 
active drugs whereby those drugs applied topically are first absorbed into the blood 
circulation and then transported to the target for elicitation of its therapeutic effect.
STRUCTURE
Structurally,  the  skin  consists  of  two  principal  parts.  The  outer,  thinner 
portion, which is composed of epithelium, is called the epidermis. The epidermis is 
cemented to the inner, thicker, connective tissue part called the dermis. Beneath the 
dermis  is  a  subcutaneous  layer.  This  layer,  also  called  the  superficial  fasica  or 
hypodermis, consists of aerolar and adipose tissues. 
Fibers from the dermis extend down into the subcutaneous layer and anchor 
the skin to it. The subcutaneous layer, in turn, is attached to underlying tissues and 
organs. The pH of the skin is normally between 5.0-6.0.
  Figure 1: Structure of skin underlying subcutaneous tissue
Epidermis
The epidermis is composed of stratified squamous epithelium and contains 
four  distinct  types  of  cells.  They  are  1)  Keratinocytes  2)  Melanocytes  Non-
pigmented  granular  dedtrocytes  formerly  known  as  3)  Langerhans  cells  and  4) 
Granstein cells. The keratinocytes of the epidermis are organized into the following 
cell layers, from the deepest to the most superficial region. 
1. Stratum basale
2. Stratum sponosum
3. Stratum granulosum
4. Stratumlucidum
5. Stratum corneum.
Dermis
The  second  principle  part  of  the  skin,  is  composed  of  connective  tissue 
containing collagenous and elastic fibres. Numerous blood vessels, nerves, glands 
and hair follicles are embedded in the dermis.
The upper region of the dermis, about one fifth of the thickness of the total 
layer is named the papillary region or layer. It consists of loose connective tissue 
containing fine elastic fibres. Its surface area is greatly increased by small, finger like 
projection called dermal papillae (pa-PIL-e). 
These  structures  project  into  the  epidermis  and  many  contain  loops  of 
capillaries.  Some  dermal  papillae  also  contain  corpuscles  of  touch,  also  called 
Meissner’s corpuscles, never endings that are sensitive to touch.
The remaining portion of the dermis is called the reticular region or layer. It 
consists  of  dense,  irregularly  arranged  connective  tissue  containing  interlacing 
bundles of collagenous and coarse elastic fibres. A small quantity of adipose tissue, 
hair follicles, nerves, oil glands and the ducts of sweat glands occupy spaces between 
the fibres. The combination of collagenous and elastic fibres in the reticular region 
provides the skin with strength, extensibility and elasticity. 
The  reticular  region  is  attached  to  underlying  organs,  such  as  bone  and 
muscle,  by  the  subcutaneous  layer.  The  subcutaneous  layer  also  contains  nerve 
endings called lamellate or paining corpuscles that are sensitive to pressure.
The permeability barrier of the skin consists of
1. The stratum corneum (10-50 micro meter thick)
2. The viable epidermis (100 micro meter thick)
3. The papillary layer of dermis (100-200 micro meter thick)
The composite structure of skin is pierced at various places by hair follicles and 
sweat glands, which occupy about 0.1-1% of total skin surface area.
Factors that affect the dissolution of drugs from topical preparations
Drugs incorporated in topical preparation may exert effect in two different ways.
 First is related to the pharmacological properties of the drug substance.
 In second exerted effect is non-specific, ointment, creams and gels constitute 
            by far the vast majority.
Dissolution of Drug in vehicle
Trans epidermal 
route
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stratum corneum
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surface
Partition into viable 
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Capillary uptake and 
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Figure 2: Scheme of Events for Percutaneous Absorption4
FACTORS AFFECTING TRANSDEMAL PERMEABILITY
The principle of transport mechanism across mammalian skin is by passive 
diffusion5 through  primarily  transepidermal  route  at  steady  state  or  through 
transappendegel  route at  non-steady state.  The factors  influencing and causing in 
transdermal permeability can be classified into three major categories:
1. Physico chemical properties of penetrants
2. Physico chemical properties of drug delivery system
3. Pathological & Physiological conditions of the skin.
Various physico-chemical  propreties of the drug like partition co-efficient, 
concentration in the vehicle, conditions, molecular size and molecular weight play a 
vital role in deciding the percutaneous absorption.
The affinity of the vehicle for the drug6 molecules solubility of the drug in the 
vehicle, pH of the vehicle can influence the release rate of the drug. The composition 
of the formulation has a great influence on percutaneous absorption of the drug .It 
may not only affect the drug release but also the permeability of the stratum corneum 
by means of hydration or absorption promoting effect7.
MECHANISTIC ANALYSIS OF DRUG PERMEATION 
THROUGH THE SKIN2
Before a topically applied drug can either locally or systemically, which must 
penetrate the stratum corneum as a skin barrier. Drug molecules may diffuse by three 
different routes.  The intact skin, the hair follicle region and the sweat gland ducts. 
But there is no total agreement on the mechanism responsible for permeation through 
intact skin. The major pathway is diffusion through the intact, cornified cells of the 
stratum  corneum.  From  this  the  dominant  pathway  to  stratum  corneum  is  by 
diffusion.
MECHANISM OF DIFFUSION THROUGH THE STRATUM 
CORNEUM2
The  stratum  corneum  is  a  multicellular  membrane  and  the  intercellular 
regions  are  filled  with  lipid  rich  amorphous  material.  In  the  dry  membrane,  the 
intercellular volume may reach 5% of the total volume. Although molecules diffuse 
through intercellular regions, the available evidence indicates that for water-soluble, 
non-electrolytes diffusion is not primarily intercellular.
The transcellular permeation is explained on the basis of relatively smaller 
diffusion coefficient.  Thus,  molecules  diffuse through intercellular  route and also 
penetrate by transcellular mechanism.
The  stratum  corneum  has  a  finite  thickness  and  so  there  is  a  period  of 
transient diffusion (lag time) after applying the drug to the skin, during which the 
rate of transfer through the skin rises to reach a steady state. The lag time (t),  is 
related thickness of the membrane (h), and the diffusion coefficient (D) of the drug, 
by the relationship, t=h2/6D.
The lag time has a direct bearing on the rate of the onset of skin penetration 
by the drug. Generally it ranges from minutes to days for the transepidermal route 
and  from  seconds  to  minutes  for  the  trans  follicular  route.  Thus  an  early 
pharmacological response would be dependant on some drug penetration by way of 
the transfollicular route.  However, once the steady state has been established, the 
contribution  of  the  shunt  to  the  overall  diffusion  becomes  negligible  and  bulk 
diffusion then occurs largely through the transepidermal route.
Damage or destruction of the stratum corneum barrier by keratolytic agents, 
cracking of  the skin and by physical  damage  by increased  absorption.  Thus,  the 
stratum corneum functions physiologically as the principle diffusion barrier. Once 
molecules pass the horny layer, they permeate rapidly through the living tissues of 
the epidermis and the dermis into the systemic circulation.
MECHANISM OF PERCUTANEOUS ABSORPTION4
The mechanism of percutaneous absorption for topical medication, which is 
important to asses the entire drug delivery system than the drug alone. It is important 
to consider. 
1. Process of drug dissolution in the vehicle
2. Diffusion of the drug
These  factors  can  be  better  understood by considering  Fick’s  law,  which 
describes drug transport across the skin, according to this,
       
J=P.C
Where,
 J = the flux (is the amount of material passing through the barrier per unit area unit 
time)
C = the difference in concentration on both sides of the membrane
P = permeability constant
P=Km.Dm/h
Where,
Km = Partition  coefficient  of  the drug molecule  between the membrane  and the 
vehicles in   
          which the drug is dissolved.
Dm = diffusion constant of the drug in the skin
   h = thickness of the membrane 
The concentration of the drug in the vehicle, the thickness of the membrane 
barrier, the mobility of the drug molecule in the barrier and the relative solubility of 
the drug in the skin and the vehicle affect the percutaneous absorption of a drug. 
Drugs applied to the skin surface reach the orifices of the sweat glands and 
the hair  follicles  directly.  Once a substance passes through the stratum corneum, 
there is apparently no further hindrance to penetration of the remaining epidermal 
layers.
Diffusion through the horny layer is a passive process, which is affected only 
by the substance being absorbed, the medium in which the substance is dispersed and 
by ambient conditions. On the other hand percutaneous absorption is a complicated 
process,  of  which  epidermal  diffusion  is  the  first  phase  and  clearance  from the 
dermis,  the  second.  The  latter  depends  on  effective  blood  flow,  interstitial  fluid 
movements, lymphatic and combination with dermal constituents.
GELS AS TOPICAL APPLICATION
Gels are “Semisolid system in which liquid phase constrained within three 
dimensional polymeric matrix in which a high degree of physical or chemical cross 
liking  has  been  introduced”.  This  network  limits  fluid  flow  by  entrapment  and 
immobilization of solvent molecules. 
This network structure is also responsible for a gel resistance to deformation 
and clear  as water  in appearance and visually aesthetically pleasing as in gelatin 
deserts, their clarity ranges from clear to whitish translucent.
Preservatives may be incorporated into the gels especially for those prepared 
from natural  sources.  Appropriate  preservatives  depending  upon the  use  and the 
gelling  agent  include  the  parabens  (0.2%),  benzoic  acid  (0.2%)  and  chlorcresol 
(0.1%).
The gels, are being used more frequently in therapeutic and cosmetic because 
of several properties such as
1. Semisolid state
2. High degree of clarity
3. Ease of application
4. Ease of removal and use.
The gels provide a faster release of drug substances, independent of water solubility 
of the drug.
GEL CHARACTERISTICS
Ideally,  gelling  agents  should  be  inert,  safe  and  non-reactive  to  other 
formulation components. The gelling agent should provide a reasonable solid like 
nature during storage that can be broken easily when subjected to the shear forces 
generated by squeezing a tube or during topical application. The gel should exhibit 
little viscosity change under the temperature variations of normal use and storage. 
The gel characteristics should match the intended use. A topical gel should not be 
tacky.
FORMULATION CONSIDERATIONS
In  the  formulation  of  gel,  the  efficiency  is  often  dependent  on  the 
composition of the vehicle. The ability of a drug in gel formulation to penetrate the 
skin and exert its effect depends on two consecutive physical events. The drug must 
first diffuse out of the vehicle to the skin surface and then, it must penetrate the 
natural  barrier  to  enter  into  the  site  of  action.  Many so  called  ‘Vehicle  effects’ 
reported in the literature are the consequences of these two diffusional processes. 
These  two  processes  are  intimately  related  and  are  dependent  upon  physico  - 
chemical properties of the drug, vehicle and the barrier.
FORMATION OF GEL
All polymer solutions are prone to settling to gels because the solute consists 
of long flexible chains of molecular thickness that find to become entangled, attract 
each other by secondary valence force. Cross linking of dissolved polymer molecule 
also causes their solutions to gel.
Gel often contract on standing and some of the interstitial liquid is squeezed 
out. This phenomenon called syneresis is due to crystallization or the formation of 
additional contact points between polymer segments on aging.
Pharmaceutical gels are random coil networks and hence further discussion 
or random coiled will be worthwhile. Random coil relation mechanisms are rooted in 
the polymer-polymer and polymer-solvent interactions with a given polymer the gel 
network increases in strength with increase in polymer concentration this result in a 
reduction of interparticle distances which subsequently leads to chain entanglement 
and further development of cross links. Continual addition of polymer strengthens 
the gel network and results in increased resistance and viscoelasticity.
Although the gel network is basically formed through polymeric interactions, 
the nature of the polymer-solvent affinity,  actually determines the integrity of the 
gel. Classical theory is distinguished between three categories of solvents.
1. Free solvents that are very mobile
2. Solvent bound as a salvation layer usually through hydrogen bonding
3. Solvent entrapped within the network structure.
The ratio  of  the  three  solvent  types  in  a  given gel,  are  dependent  on the 
polymer  concentration  and  the  solvent  affinity  for  the  polymer.  Solvent  affinity 
governs the extension of this random coil. The greater the solvent affinities the more 
coil expands and entangles with adjacent coils to form cross-links.
In a good solvent, solvent molecules interpenetrate the polymer chains and 
the salvation  layer  is  enhanced,  which  facilitates  random expansion and network 
formation. In a poor solvent, the polymer chain contract to minimize solvent contact 
reducing the effective number of cross-links and weakens the gel network structure.
Gelation theory can be readily applied when formulating gel products and 
some of the desirable attributes of gel formulations are in the following order. For 
optimum consumer appeal the gel should have good optical  clarity and sparkling 
appearance. To preserve product integrity, the gel should maintain its viscosity at all 
temperatures.
STABILITY TESTING OF GEL FORMULATION
Stability  is  one  of  the  important  factor  apart  from  the  formulation.  So 
evaluation  of  stability  in  gels  is  perhaps  one  of  the  important  criteria.  Chemical 
integrity of the dispersed active ingredients and the physical characteristics the gel 
system needs to be studied together.  Most gels exhibit  non-newtonion rheological 
behavior  and  they  can  be  evaluated  by  a  Rotational  Viscometer  like  Brookfield 
Viscometer  and  Cone  Plate  Viscometer  which  operate  at  different  shear  rates. 
Similarly gels can be evaluated for spreadability.
 A useful  empirical  test  is  the measurement  force required to extrude the 
material from a deformable tube. While not strictly a test of product characteristics 
due to inclusion of the force necessary to deform the container, the method applies 
shear  rate  exceeding the yield  value and exhibiting plug flow. Such flow can be 
measured by the use of pentrometer. 
Yield  value  within  the  range  of  100-1000  dyne/cm2 is  classified  as 
spreadable. Below this range the material is too soft and flowing, above this range, it 
is hard and can not be spread. Apart from the above test, other tests which are used to 
examine semisolid products in general are also used for gels.
Freeze-thaw cycling test can be used to see whether separation or synthesis 
occurs. Storage of samples at various temperatures gives good information about the 
storage requirements for that gel. The elevated temperature should not be more than 
450-500C.
Gels and jellies now days have gained more importance and extensive studies 
on  release  characteristics  have  revealed  that  the  active  ingredients  are  better 
percutaneously absorbed from the gel based formulation, than from the creams and 
ointment base. 
The  ointment  base  has  limitation  in  miscibility  with  the  alcohol  and  the 
emulsion based creams lead to crack if the alcohol content is more. It will be no 
wonder if the gel based formulation greatly replaces ointments and creams in future.
VIRAL DISEASE 8
The Herpes virus family contains over a hundred species of enveloped DNA 
viruses that affect humans and animals.  They are characterized by their ability to 
establish latent infections enabling the virus to persist indefinitely within infected 
hosts and to undergo periodic reactivation.
Herpes simplex virus belongs to a family of viruses called  Herpesviridae. 
They are composed of a central DNA core and a protein capscid with 162 hollow 
cylindrical  apsomers.  This  nucleocapsid  is  surrounded by an envelope  forming  a 
virus particle with an overall diameter of 130-180nm.
Herpes simplex virus usually affects  tissues of ectodermal  origin,  such as 
skin, mucous membrane and the nervous system. After the attachment to specific 
receptors on the surface of the human cells the virion loses its envelope to the cell 
membrane and enters the cells by pinocytosis. 
The DNA released into the cells travels to the nucleus. In namely thymidine 
kinase  and  DNA  polymerase.  Viral  proteins  synthesized  in  the  cytoplasm  are 
transferred to the nucleus where the nuleocapscid is assembled. The nucleocapscids 
packed with such particles before it ultimately undergoes cell lysis and releases the 
infectious particles.
Virus types
The family  of  Herpes  viruses  is  very large,  and its  members  infect  most 
animal species. There are eight recognized herpes viruses that affect humans. These 
viruses are divided into three groups are listed in Table 1.
Table 1: Virus types
Groups
Species
(Official name)
Species
(Common name)
Site of latent 
infection
Alpha-herpes virus
Human herpes virus 
type 1
Human herpes virus 
type 2
Human herpes virus 
type 3
Herpes simplex 
virus type1(HSV-1)
Herpes simplex 
virus type2(HSV-2)
Varicella zoster 
virus (VZV)
Neurons
Neurons
Neurons
Beta-herpes virus
Human herpes virus 
type 4
Human herpes virus 
type 5
Human herpes virus 
type 6
Cytomegalovirus
Human B cell 
lymphtropic virus
R K virus
Secretory glands, 
kidneys, other organs 
and tissues
Lymphoid tissues
Lymphoid tissues
Gamma-herpes virus
Human herpes virus 
type 7
Human herpes virus 
type 8
Epstein-Barr virus
     --------
Lymphoid tissues
   -------
Worldwide, more than 90 percent of humans have been exposed to HSV-1 and are 
seropositive for this virus by the fourth decade of life. HSV type 1 is usually isolated 
from lesions in and around the mouth and is transmitted by direct contact or droplet 
spread from the cases or carriers.  HSV type  2 is  responsible  for the majority  of 
genital herpes infections and is commonly transmitted venerially.
HERPES SIMPLEX VIRUS INFECTION 
Herpes Simplex Virus (HSV) is one of the most common agents infecting 
humans of all ages. The virus occurs and produces a variety of illness, including 
mucocutaneous infections, infections of the CNS, and occasionally infections of the 
visceral organs. Infections in children can include neonatal disease, mucocutaneous 
infections during childhood and adolescence, and serious disease in individuals who 
are immunocompromised. 
Genital HSV infection in older adolescents and adults is a major public health 
problem. This increased prevalence of genital HSV infections posses major threats to 
newborns  because  most  infections  in  neonates  are  acquired  perinatally.  Neonatal 
HSV infection is a disease with high morbidity and mortality rates.
CLINICAL FEATURES
The clinical manifestations depend on the site of action, age and immune 
status of the host, and the antigenic type of the virus.
Cutaneous infections 
The most common site is the face on the cheeks, chin, around the mouth and 
on the forehead. Lesions may also appear on the buttocks in infants as napkin rash. 
“Eczema  herpeticum”  is  a  generalized  eruption  caused  by  herpes  infection  in 
children suffering from eczema.
Mucosal infections
The buccal  mucosa is the site most  commonly affected.  Gingivostomatitis 
and pharyngitis are the most frequent conditions in primary infection and  Herpes  
labialis in recurrent infection.  The vesicles may ulcerate  and become secondarily 
infected.
Ophthalmic infections
The most common cause is corneal blindness and acute keratoconjuctivitis 
may occur by itself or by extension from facial herpes. Follicular conjunctivitis with 
vesicle formation on the lids is another manifestation.
Nervous system infections
HSV can cause sacral autonomic dysfunction also rarely transverse myelitis 
or the Guillian Barre syndrome. HSV has been implicated in the etiology of Bell’s 
palsy.  HSV  encephalitis  has  an  acute  onset  with  fever  and  focal  neurological 
symptoms.  Brai  biopsy  was  employed  in  diagnosis  for  instituting  early  specific 
therapy.
Genital infections
In  men,  the  lesions  occur  mainly  on  the  penis  or  in  the  urethra  causing 
urethritis.  In  women  the  cervix,  vagina,  vulva  and  perineum  are  affected.  The 
primary infection is  usually more serious,  accompanied by systemic  features  like 
fever and malaise. Both type of HSV may cause genital lesions, though HSV 2 is 
responsible more frequently and causes many more recurrences.
DIAGNOSIS
The diagnosis of herpes virus infection may be made by microscopy, antigen 
or DNA detection, virus isolation or serology. 
Microscopy:  Smears  are  prepared  from the  lesions,  preferably  from the  base  of 
vesicles and stained with 1% aqueous solution of toluidine blue for 15 seconds. The 
virus particle may also be demonstrated under the electron microscope.
Virus isolation: Human embryonic kidney, human amnion and many other cells are 
susceptible  for  this.  Vesicle  fluid,  Spinal  fluid,  Saliva  and  Swabs  may  be  used. 
Typical cenotaphic changes may appear as early as in 24-48hrs but cultures should 
be observed for two weeks.
Serology:  Serological  methods  are  useful  in  the  diagnosis  of  primary  infections. 
Antibodies develop within a few days of infection and rise in the titre of antibodies 
may be demonstrated by ELISA, neutralization or complement fixation tests.
TREATMENT
Idoxyuridine is used topically in eye and skin infections were one of the first 
clinically successful antiviral agents. The introduction of Acyclovir and Vidarabine 
enabled the effective management of deep and systemic infections. Early treatment 
with  intravenous  acyclovir  has  improved  the  outcome  of  encephalitis.  Oral  and 
topical use may help in less serious conditions.  Valacyclovir  and Famciclovir are 
more effective oral agents.
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Varicella Zoster Virus (VZV) is one of the most common viral infections of 
the peripheral nervous system. Latent infection of neurons in the sensory ganglia of 
the  spinal  cord  and brain  stem follows  chicken  pox,  and reactivation  leads  to  a 
painful, vesicular skin eruption in the distribution of sensory dermatomes (Shingles), 
most frequently thoracic or trigeminal. 
The virus may be transported along the sensory nerves to the skin , where it 
establishes  on  active  infection  of  epidermal  cells.  In  small  portions  of  patients, 
weakness is also apparent in the same distribution. Although the factors that give rise 
to  reactivation  are  not  fully  understood,  decreased  cell-mediated  immunity  is  of 
major importance in some cases.
Affected ganglia show neuronal destruction and loss, usually accompanied by 
abundant mononuclear inflammatory infiltrates, regional necrosis with hemorrhage 
may also be found. Pheripheral nerve shows axonal degeneration after the depth of 
the sensory neurons. Focal destruction of the large motor  neurons of the anterior 
horns  or  cranial  nerve  motor  nuclei  may  be  seen  at  the  cones  ponding  levels. 
Intranuclear inclusions generally are not found in the pheripheral nervous system.
Pathophysiology
The  host  immunologic  mechanisms  suppress  replication  of  the  virus. 
Reactivation can occur if host immune mechanisms are compromised. This may be 
caused by medications,  illness,  malnutrition,  or by the natural  decline in immune 
function with aging. Upon reactivation, the virus migrates along sensory nerves and 
produces sensory loss, pain and other neurologic complications. If motor nerve roots 
are also involved, weakness can develop in addition to sensory changes.
Mortality/Morbidity
• Severe pain and insomnia are most bothersome to patients. About 95% of 
                  patients with  zoster experience severe pain during the illness. 
• Other presentations of zoster, including ocular (keratitis) and spinal cord 
                 (myelitis) presentations may result in additional morbidity.
o Bacterial super infection (impetgenzation) of vesicular skin lesions can 
occur. The vesicular eruption of VZV infection may be more difficult to 
diagnose in  patients with   darker skin.
Causes
Sex: Varicella Zoster Virus infection occurs with equal frequency in males and 
females.
Age: 
 After primary infection, zoster can occur at any age. However, the risk  of 
zoster increase with age.
  The risk of postherapeutic neuralgia also increases with advancing age.
 Herpes zoster (Shingles)
• The  most  common  presentation  is  the  shingles  vesicular  rash, 
which most commonly affects a thoracic dermatome.
• After a prodermal illness of pain and paresthesias,  erythematous 
muscles  papules develop and progress to vesicles within 24 hours. 
The vesicles eventually crust and resolve.
• Pain and sensory loss are the usual symptoms, but motor weakness 
also  occurs  and  is  frequently  missed  on  examination.  Motor 
weakness  results  when  the  viral  activity  extends  beyond  the 
sensory root to involve the motor root. 
Diagnosis 
Diagnosis is usually clinical. Smears are prepared by scraping the base of the 
early vesicles and stained with toluidine blue. Electron microscopy of the vesicle 
fluid may demonstrate the virus with typical herpes morphology,
Prophylaxis and Treatment
A live varicella vaccine was developed by serial passage in tissue culture. 
Given subcutaneously, it induced good antibody response but it was liable and had to 
be stored frozen. A modified lyophilized form of the vaccine is now available which 
can  be  stored  between  20C-80C.  Specific  treatment  is  indicated  mainly  in 
immunodeficient and elderly subjects and those with complications such as varicella 
pneumonia,  encephalitis  and disseminated  zoster.  Acyclovir  and  Famciclovir  are 
effective. Corticosteroids are contraindicated in varicella as they enhance the risk of 
pneumonia and disseminated disease.  
Antiviral agents10
Table 2: Antiviral agents
Drug Name Acyclovir Valacyclovir
Famciclovir
(Famvir)
Penciclovir
(Denavir)
Description
Inhibits activity of 
HSV-1, HSV-2, 
available as oral 
suspension, tablet, 
capsule, injection and 
topical.
Prodrug rapidly 
converted to active drug 
acyclovir, use in 
adolescent HSV 
infection.
Transformed to 
active nucleoside 
analogue penciclovir, 
inhibits HSV DNA 
synthesis
1% cream 
approved for 
orolabial HSV 
infection and 
inhibit viral DNA 
synthesis
Adult Dose
200mg or 400mg 
5times for 7-10 days, 
800mg 3times for 2 
days.
1000mg for 10days and 
500mg for 3 days
250mg for 7-10 days Apply and cover 
lesion for 4 days
Pediatric Dose
15mg/kg 5times for 
7days, 5mg/kg IV for 
7-10 days
Not established Not established Not FDA approved 
for children
Contraindications Hypersensitivity Hypersensitivity Hypersensitivity Hypersensitivity
Interactions
Zidovudine or 
probenecid prolongs 
half-life and can 
increase CNS toxicity
Zidovudine,probencid 
and cimetidine prolongs 
half-life and can 
increase CNS toxicity
Probenecid or 
cimetidine may 
increase toxicity.
Not reported
Precautions
Renal dysfunction can 
occur during high 
dose IV 
administration ; can 
minimize effect by 
using slow infusion.
Caution in renal failure 
and with co 
administration of 
nephrotoxic drugs.
Caution in renal 
failure and with co 
administration of 
nephrotoxic drugs.
Mild erythema 
possible, do not 
apply to mucosal 
surfaces.
LITERATURE REVIEW
Jocelyne Piret et al11., have carried out the topical efficacies of foscarnet and 
acyclovir  incorporated  into  a  polyoxypropylene-polyoxyethylene  polymer  were 
evaluated and compared to that of 5% acyclovir ointment by use of a murine model 
of cutaneous herpes simplex virus type 1 infection in mice, whereas the foscarnet 
formulation  has  less  of  an  antiviral  effect  but  a  single  application  given  24  hrs 
postinfection  resulted  in  a  significantly  higher  efficacy  of  the  formulation  of 
acyclovir than of the acyclovir ointment. Acyclovir incorporated within the polymer 
was also significantly more effective than the acyclovir ointment when treatment was 
initiated on day 5 postinfection.  The higher efficacy of the acyclovir  formulation 
than  of  the  acyclovir  ointment  is  attributed  to  the  semi  viscous  character  of  the 
polymer, which allows better penetration of the drug into the skin.
Min  Jiang  et  al12.,  have  studied  In  vitro  evaluation  of  percutaneous 
absorption  of  Acyclovir  product  using  intact  and  Tape-stripped  human  skin, 
Acyclovir ointment (~10 mg) spiked with H-labeled acyclovir was applied onto the 
stratum corneum/epidermis side. The skin sections were continually perfused on the 
dermis  side  with  sterilized  culture  medium.  After  24  hours,  the  percentages  of 
acyclovir-derived radioactivity in different components were obtained with the intact 
skin sections through human skin layers and therefore can potentially be used for 
dermal formulation characterization and development.
L.  Trottet  et  al13., were  studied  all  acyclovir  cream  formulations  were 
bioequivalent, Topical acyclovir cream containing 40% propylene glycol (PG), the 
optimum found for skin penetration  in vitro skin permeation  study compared the 
innovator  cream  with  two  generics  containing  about  15%  PG  and  10  generics 
containing 0–15% PG were tested and ACV analyzed by LC-MS-MS the studies 
suggest that not all marketed ACV creams are bioequivalent to the clinically proven 
innovator.
Sintov et  al14.,  The  present  invention  relates  to  an  antiviral  topical 
pharmaceutical  composition  for  treating  viral  diseases  of  the  skin  or  mucosa 
comprises  a  poorly  soluble  antiviral  nucleoside  derivative  in  gel  formulation,  it 
enhances the absorption of acyclovir and the formulation containing a gelling agent 
carboxylic acid salt or dicarboxylic acid salt, to compare several acyclovir gels and 
one  w/o  cream  that  were  formulated.  The  in  vitro  percutaneous 
absorption/penetration of acyclovir from the gel or cream vehicles was carried out 
using  Franz  diffusion  cell  system and  the  efficacy of  a  drug-containing  gel  and 
ZOVIRAX  commercial  cream  was  evaluated  as  compared  to  a  non-treatment 
control.  A guinea  pig model  was selected  for  the cutaneous HSV-1, because the 
model mimics the human herpes simplex labialis infection.
S. S. Dubhashi et al15.,   studied skin permeation of acyclovir  by HPTLC 
method,  in  this  study Separation  of  guinea  pig  skin  proteins  and  acyclovir  was 
achieved by employing a mobile phase consisting of chloroform–methanol–ammonia 
(15:9:4,  v/  v/v)  on  precoated  silica  gel  60F254  aluminum  plates.  Densitometnic 
analysis was carried out at 255 nm. The average recoveries of 101.8 and 100.1% 
were recorded for two marketed preparations studied. The method was employed to 
optirmize topical liposomal gel formulation of acyclovir on basis of maximum skin 
permeation.
Chun Yang et al16., have worked Chemical stability, Enzymatic hydrolysis 
and Nasal uptake of amino acid ester prodrugs of Acyclovir and the work was to 
improve  nasal  absorption  of  impermeable  small  drug  molecules  by  amino  acid 
prodrug approach, Acyclovir was selected as a model drug.
Castela N et al17., Ganciclovir ophthalmic gel in herpes simplex virus rabbit 
keratitis:  intraocular  penetration  and  efficacy  A  chronic  administration  of  three 
ganciclovir gels (0.2%, 0.05%, 0.0125%) was compared with a placebo gel and a 3% 
acyclovir  ophthalmic ointment  in the treatment  of HSV-1 rabbit  keratitis.  All  the 
ganciclovir  gels  showed  a  clinical  efficacy:  the  efficacy  was  slower  than  using 
acyclovir ointment, no significant difference could be shown between the 0.2% and 
0.05% ganciclovir gels or the 0.05% ganciclovir gel and the acyclovir treatment on 
viral isolation, The distribution of ganciclovir and acyclovir into the rabbit eyes were 
similar and this study suggests a comparable activity on HSV-1 superficial keratitis 
between 0.05%, 0.2% ganciclovir gels and 3% acyclovir ointment.
Hoh HB, Hurley C et al18., Randomized trial of ganciclovir and acyclovir in 
the treatment of herpes simplex dentric keratitis, this study was designed to assess 
the relative efficacy of topical ganciclovir 0.15% gel and acyclovir 3% ointment in 
the treatment of herpes simplex dendritic keratitis, both treatment  were administered 
on a five times daily basis to patients suffering from herpes simplex keratitis There 
was no statistically significant difference detected in the rate of healing between the 
two treatment  groups over  the course of  the  trial  the relative  efficacy  of  topical 
ganciclovir  and  acyclovir  in  the  treatment  of  herpes  simplex  dendritic  keratitis 
showed  that  both  treatment  were  equally  effective  in  the  viral  induced  corneal 
ulceration.
Eric M. Morrel et al19., Transport delivers unprecedented levels of acyclovir 
with  novel  five  percent  gel  formulation,  the  topical  treatment  of  dermatological 
conditions were announced preliminary results from a recently completed Phase I 
safety  and  pharmacokinetic  study  with  the  SoloVir  electro  kinetic  transdermal 
system and five-percent acyclovir gel formulation. Treatment of a herpetic episode 
with the SoloVir  will consist of a single ten minute treatment, each subject received 
four  treatments,  a  single  ten  minute  application  delivered  approximately  40 
micrograms of acyclovir  to the circulation after passing through stratum corneum 
and locally depositing in the epidermis.
C. Martnez-Sancho et al20.,  Poly (D, L-lactide-co-glycolide) micro spheres 
for long-term intravitreal  delivery of acyclovir  :  influence of  fatty and non-fatty 
additives. In this work, acyclovir containing Poly (D,L-lactide-co-glycolide) micro 
spheres  were  prepared  by the  solvent  evaporation  method.  Seven additives  were 
incorporated in the micro spheres to modulate the in vitro release rate of the drug and 
these are evaluated by scanning electro microscopy, Granulometric analysis showed 
that particle size distribution. The release of acyclovir from these micro spheres was 
adjusted to a zero order kinetics.
Massimo  Fresta et  al21.,  Studied  ocular  tolerability  and  in  vivo 
bioavailability  of   PEG-coated  and  polyethyl-2-cyanoacrylate  nanosphere-
encapsulated Acyclovir and were prepared by an emulsion polymerization process in 
the micellar phase and characterized, presence of PEG also resulted in a changing the 
zeta  potential  but  zeta  potential  was  not  influenced  in  vitro  drug  release  was 
determined in both 7.4 phosphate buffer and plasma.  The ocular  tolerability  was 
evaluated  by  the  in  vivo  Draize  test  and  the  aqueous  humour  acyclovir  was 
determined by HPLC, from this the two formulations showed significant increase of 
drug levels with the free drug.
Elaine D. Mackowiak et al22., studied Prevention and Treatment of Cold 
sores, the antiviral drugs approved by  FDA for the treatment of herpes labialis are 
Penciclovir 1% cream, acyclovir 5% ointment, and valcyclovir , Acyclovir  was the 
first oral antiviral drug approved by  FDA for use in HSV-2 and VZV infections in 
immunocompetent  patients  and  for  HSV-1  infections  in  immunocompromised 
patients, the addition of sodium lauryl sulfate 5% to a foscarnet 3% gel formulation 
increased its protective effect against HSV-1,  oral famciclovir (Famvir) in doses of 
250 mg or 500 mg twice daily started 24 hours before laser skin resurfacing reduced 
reactivation  of  cold  sores  by  90%  in  a  series.  Another  drug,  valacyclovir  was 
recently approved by  FDA for the prevention of cold sores in people infected with 
HIV. Valacyclovir is the prodrug of acyclovir. 
Loice Kikwai et al23., have studied in vitro and in vivo evaluation of Topical 
formulations of Spantide II . The lotion and gel was formulated with and without n-
methyl-2-pyrollidine as a penetration enhacer. The release of Spantide II from gel 
was studied using microporous polyethylene and polypropylene membranes in Franz 
Diffussion cell, in vitro percutaneous absorption from gel and cream was evaluated 
using  hairless  rat  skin  in  above  setup  and  the  in  vivo  anti-inflammatory  was 
evaluated in mouse model. Among different gels studied, PF127 gel showed highest 
(70fold)  release  compared  with  HPMC and  HPC gels.  Lotion  and  gels  with  or 
without  n-methyl-2-pyrollidine  showed no detectable  levels  of  Spantide  II  in  the 
receiver compartment of the Franz diffusion cell.
Aly,  A.  M  et  al24., have  studied  Formulation  and  in  vitro evaluation  of 
fluconazole  topical  gel,  Seven  gel  formulations  were  prepared  using  sodium 
carboxymethylcellulose, sodium alginate, hydroxypropyl  methylcellulose (HPMC), 
plantago, agar, pectin, and tragacanth containing 2% w/w fluconazole. The in vitro 
release was conducted using an artificial cellophane membrane. The permeation of 
fluconazole through hairless mouse skin was also studied. The receptor solution was 
saline phosphate buffer (pH 7.4). It was found that, plantago and sodium carboxy 
methyl  cellulose  are  the  best  gel  bases  for  this  purpose.  Fluconazole  permeated 
through the hairless mouse skin exceeded the MIC from all the tested gel formulation 
within 30 minutes, except in the case of pectin where the MIC was reached between 
30 and 90 minutes.  It is concluded that fluconazole can be used topically,  as gel 
formulations.
Jocelyne  Piret  et  al25.,   carried  out  Sodium Lauryl  Sulfate  increases  the 
efficacy of a topical formulation of  Foscarnet against Herpes Simplex Virus Type 1 
Cutaneous lesions in Mice, the addition of 5% SLS to this gel formulation markedly 
reduced the mean lesion score. The improved efficacy of the foscarnet formulation 
containing SLS could be attributed to an increased penetration of the antiviral agent 
into the epidermis also inhibited the HSV-1 strain. Foscarnet in phosphate-buffered 
saline decreased in a dose-dependent manner the viability of cultured human skin 
fibroblasts.  This  toxic  effect  was  markedly  decreased  when  foscarnet  was 
incorporated  into  the  polymer  matrix.  The  use  of  gel  formulations  containing 
foscarnet and SLS could represent an attractive approach to the treatment of herpetic 
mucocutaneous lesions, especially those caused by acyclovir-resistant strains.
             Reddy M Sreenivasa et al26., have studied Preparation and evaluation of 
minoxidil  gels  for  topical  application  in  alopecia,  using  carbopol,  hydroxypropyl 
cellulose,  hydroxypropyl  methylcellulose  and  combination  of  hydroxypropyl 
cellulose, hydroxypropyl methylcellulose. The gels were evaluated for drug content, 
viscosity determination, in vitro permeation (across dialysis membrane and mouse 
skin), skin irritation and stability at 4, 25 and 37° tests. The drug content of the gels  
was  found to  range from 96.40±0.57 to  98.10±0.32%.  The viscosity  of  the  gels 
ranged  between  13,780±100  and  24,950±150  cps.  The  drug  permeation  across 
dialysis membrane from all the formulations at the end of 24 h was almost same and 
ranged between 92.05±1.52 and 93.52±1.95%, the percentage release of drug was 
found  to  increase  in  the  following  order  of  the  polymer  composition: 
HPC>Carbopol>HPMC>HPMC+HPC.  All  the  gel  formulations  released  almost 
similar amounts of drug (90.05±1.92 to 91.56±1.65%) across the mouse skin. The 
prepared gels did not produce any dermatological reactions  and the gels were found 
to be physically stable at all temperature conditions for 3 months.
Joseph M Beaurline et al27., have carried out Gel formulations for topical 
drug delivery,  relates to improved pharmaceutical gel formulations for the topical 
delivery of drugs,  gel formulations including a drug  4-amino-2-ethoxymethyl-α,α-
dimethyl-1H-imidazo[4,5-c]quinoline  -1-ethanol,   gelling  agents  colloidal  silicon 
dioxide, triacetin and propylene glycol. The drug is preferably, which has been found 
to be sufficiently  soluble  and chemically  stable  in  gel  formulations,  inclusion  of 
propylene  glycol  thickens the  gel  formulations  that  may act  as  a  solvent  for  the 
colloidal  silicon dioxide  and as  a  solubilizer  for  the  drug and then  heating  with 
mixing to a temperature of about 50-55° C when the drug appears to be completely 
dissolved, the resulting mixture is sheared on a high speed propeller mixer until a 
homogeneous gel is formed. Drug release test was carried by using a modified Franz 
diffusion  cell  10  of  the  type,  a  section  of  synthetic  membrane  11 (microporous 
polyethylene  film)  was used and 0.1M sodium acetate  buffer,  pH 4.0)  used as a 
medium.  A modified Franz diffusion cell 20 of the type is used in In Vitro Skin 
Penetration Test Method using two types of skin are, hairless mouse skin and human 
cadaver skin.
Purushothamam rao K et al28., have studied development and evaluation of 
controlled release ciprofloxacin hydrochloride medicated dental paste, Formulations 
using various mucoadhesive polymers such as MC, HPMC, HEC, and NaCMC as 
release  retardants.  The  formulations  were  subjected  for  various  physicochemical 
tests like pH, spreadability, extrudability, drug content, in-vitro release and stability 
studies,  the  release  studies  were  carried  over  a  period  of  6hrs  and  release  was 
dependant  on  the  type  of  polymer  used.  Stability  studies  showed  no  significant 
variations in pH, spreadability, viscosity, extrudability and drug content. 
Devalina Law et al29.,  have studied Ritonavir-PEG 8000 at  ritonavir  is  a 
substrate of P-glycoprotein and the oral absorption of ritonavir could be limited by 
both dissolution and permeability.  The effect of enhanced dissolution rate on oral 
absorption  was  explored;  specifically  PEG-amorphous  ritonavir  solid  dispersions 
were prepared with different drug loadings.  In vitro evaluation was conducted in 
0.1N HCL with a USP apparatus I, the dissolution measurements of the two solid 
phases  indicated  a  10-fold improvement  in  this  comparison  study.  In  vivo  study 
results indicate that amorphous solid dispersions containing 10-30% drug exhibited 
significant increases in AUC and Cmax over crystalline drug. However, both in vitro 
dissolution and bioavailability decreased with increasing drug load. 
Antiviral  activity  of  thiazole  derivatives  in  chick  embryo  was  studied  by 
Alka Tripathi et al30., The antiviral activity was evaluated against SRV in vitro and 
in  vivo method.  The compounds  were also  tested  against  Ranikhet  disease  virus 
(RDV) in a stationary culture of chorioallantoic membrane of chick embryo, in vitro 
exhibited a mild inhibitory effect and showed significant inhibition in vivo ranging 
from 65%-75%.
Alvara Jimenez-Kairuz et al31  has studied mechanism of Lidocaine release 
from  carbomer-lidocaine  hydro  gels,  delivery  rates  of  free  base  lidocaine  were 
measured  in  a  Franz-type  biocompartmental  device  using  water  and  Nacl  0.9% 
solution as receptor media. Carbomer-lidocaine hydro gels behave as a reservoir and 
pH suggests that, under the main conditions assayed, dissociation of (R=COO- LH+) 
is  that  controls  the  releasing  rate.  Accordingly,  release  rate  was  increased  upon 
addition of a second counter ion (i.e. Na+), into the matrix of the gel.
Bryan J.  Campbell  et  al32.,  have  studied  Systemic  absorption  of  topical 
Lidocaine in normal volunteers, patients with post-herpetic Neuralgia and patients 
with acute Herpes Zoster,  the study was to characterize the absorption profile  of 
lidocaine from patch and gel formulations in normal volunteers, patients with post-
herpetic  neuralgia  and  patients  with  acute  herpes  zoster.,  the  primary  active 
metabolite of lidocaine after application gel or patches was minimal in all types of 
patients. Considering the systemic absorption and toxicity of lidocaine seems not to 
be a significant risk. 
Lalezari  J et  al33.,  A randomize  double  blind,  placebo-controlled  trial  of 
cidofovir  gel  for  the  treatment  of  acyclovir-unresponsive  mucocutaneous  herpes 
simplex virus infection in patients with AIDS, The safety and efficacy of cidofovir 
gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS 
patients was evaluated in a randomized,  double-blind,  multicenter  trial.  Cidofovir 
(0.3% or 1%) or placebo gel  was applied once daily for 5 days  Application  site 
reactions occurred in 25% of cidofovir-treated and 20% of placebo-treated patients; 
none was dose-limiting.  Cidofovir  therapy provided significant  benefits  in  lesion 
healing, virologic effect, and pain reduction.
Ying-Yue Wang et al34.,  have studied In vitro and in vivo evaluations of 
topically  applied  capsaicin  and  nonivamide  from  hydro  gels  and  compare  with 
commercialized creams. Both skin stripping technique and Hexameter were applied 
to evaluate the level of capsaicin and nonivamide retained in stratum corneum and 
skin erythema in vivo,  the in vitro capsaicin permeation showed higher levels  in 
cationic chitosan and anionic CMC hydro gels than creams and the cream reduced in 
vivo skin erythema however, the dose-dependence was not observed in hydro gels, 
so  this  study indicates  correlation  between  in  vitro  skin  permeation  and  in  vivo 
erythema response. 
SCOPE AND PLAN OF WORK
Acyclovir is a broad-spectrum anti-viral agent against Herpes Simplex Virus 
(HSV) and Varicella  Zoster  Virus  (VZV).  Two conditions  like Chicken pox and 
Shingles caused by VZV, which infects mucous membrane, skin and neurons. 
Acyclovir  is  poorly  water  soluble  and  poor  oral  bioavailability,  hence 
intravenous  administration  is  necessary  if  high  concentrations  with  fewer  side-
effects.
Therapy for this disease is based on the application of anti-viral  agents to 
inhibit virus growth. Topical semi-solid preparations are designed to produce local 
activity. Creams, gels, ointments and pastes are some of the topical semi-solids in 
use for many decades.
 These are evolved with little understanding or absorption mechanism. But 
now gels have gained more and more importance because the gel formulations have 
better percutaneous absorption than Creams and Ointments.
Gels are gaining more popular due to ease of application, undetectable to eye 
and neither tacky nor greasy.
Hence  a  study on  formulation  and  evaluation  of  Acyclovir  gel  was  as  a 
principal objective for anti-viral activity.
Acyclovir  appears  to  be  more  active  anti-viral  agent  and  is  usually  well 
tolerated. It works by stopping the spread of the HSV in the body. Non-availability 
of Acyclovir gels in the market is one of the reasons for the study. So the aim of 
project work is to develop gel formulation containing Acyclovir 
The following objectives are the main considerations in the research work:
 Compatibility study of Drug with different polymers like Carbopol,   
                 Hydroxypropyl methyl cellulose and Sodium Carboxy methyl cellulose.
 Designing of trial formula for different  concentration of each polymer
 Optimization of the formula to attain all gel characteristics
 Selection of suitable formula from each polymer and preparation of the gel 
                        formulations
 Evaluation of  the prepared gels for                      
• Drug content
• pH 
• Viscosity 
• Spreadability 
• Extrudability  
 In-vitro drug release for each gel formulation and compare the 
results and also study the effect of permeation enhancer for each 
formulation.  From  this  the  best  formulation  is  selected  for 
further studies
 Stability study of the selected formulation to perform for three 
months in different storage conditions
 In-vivo  evaluation  of  the  selected  formulation  to  perform by 
using Albino Rabbits and comparison with marketed Acyclovir 
topical formulation.
PROFILE OF DRUG AND CHEMICALS
Acyclovir – Drug profile35
Chemistry                                                                           
                                          
      Figure 3: 2-amino-9-((2-hydroxyethoxy)methyl)-3,9-dihydro-6H-purin-6-
one
      Descripton36
Colour : White crystalline powder 
Odour : Characteristic
Taste : Bitter to alkaline
Solubility: Slightly soluble in water, very slightly soluble in alcohol, freely soluble 
in Di methyl sulfoxide and dilute solutions of mineral acids and alkali hydroxides.
CLINICAL PHARMACOLOGY 10
Acyclovir contains a partial nucleoside structure, the sugar ring is replaced by 
an  open-chain  structure.  It  is  selectively  converted  into  aciclo-guanosine 
monophosphate (aciclo-GMP) by viral thymidine kinase, which is far more effective 
(3000 times) in phosphorylation than cellular thymidine kinase. 
Subsequently, the monophosphate form is further phosphorylated into active 
triphosphate form, aciclo-guanosine triphosphate (aciclo-GTP), by cellular  kinase. 
Aciclo-GTP is a very potent inhibitor of viral DNA polymerase, it has approximately 
100 times greater affinity for viral than cellular polymerase.
 As  a  substrate,  aciclo-GMP is  incorporated  into  viral  DNA,  resulting  in 
chain termination.Viral enzymes cannot remove aciclo-GMP from the chain, which 
results  in inhibition of further  activity of DNA polymerase.  Aciclo-GTP is  fairly 
rapidly metabolized within the cell, possibly by cellular phosphatases.
Acyclovir is specific to viral-infected cells with low toxicity and which is less 
toxic  than  earlier  generation  of  antiviral  agents  and  as  such  represents  a  major 
therapeutic advance.
Acyclovir can be considered a prodrug, it is administered in an inactive or 
less active and is metabolized into a more active species after administration.  
Acyclovir  is  active  against  most  species  in  the  herpes  virus  family,  in 
descending order of activity:
• Herpes simplex virus type I (HSV-1)
• Herpes simplex virus type II (HSV-2)
• Varicella zoster virus (VZV)
• Cyto megalo virus (CMV)
• Activity is predominantly against HSV and VZV, it is only limited           
                 efficiency against EBV and CMV.
Pharmacokinetics
Acyclovir  is  poorly water soluble and has poor oral  bioavailability,  hence 
intravenous administration is necessary if high concentrations are required.  When 
orally administered,
• Bioavailability           - 10-20%
• Protein binding          - 30%
• Metabolism               - Viral thymidine kinase
• Elimination half life  - 2 -3 hours
• tmax                             - 1-2 hours
• Acyclovir has a high distribution rate
o Excretion                - Renally excreted, partly by glomerullar filtration and 
                                        Partly by tubular secretion.
Adverse Effects
• Common adverse drug reactions associated with systemic Acyclovir 
                 therapy include : nausea, vomiting and headache.
• Infrequent adverse effects include: confusion, dizziness, edema, sore 
                 throat, constipation, abdominal pain and weakness.
• Rare adverse effects include: coma, seizures, neutropenia, leucopenia,   
                 crystalluria, hepatitis and anaphylaxis.
Therapeutic Use
Anti-viral activity against Herpes Simplex Virus and Varicella Zoster Virus 
infections in immunocompromised patients.
Toxicity
Its use should be avoided during pregnancy.
Drug interaction
      Zidovudine or probenecid prolongs half-life and can increase CNS toxicity
Dosage forms 
Intravenous Infusion; Capsules; Tablets; Suspension; Topical Cream; Topical 
Ointment
Dose37
Oral 
200mg 5 times daily every four hours for 5-10 days,
           400mg 5 times daily  for 5 days in severly immunocompromised patients
           800mg 4-5 times daily for 5-7 days.
Topical 
5% ointment/cream 5-6 times daily every 3-4 hours for 5-10 days
Contraindications
                                Hypersensitivity
Trade Name Preparation Dose Manufacturer
ACIV Tablets 200 and 800mg Zee lab
ACIVIR
Tablets,
Injection,
Cream 5%,
Ointment 3%
200,400 and 800mg
10ml
5gm
5gm
Cipla
ACIVIRALL DT-Tablets 200 and 400mg Finecure
ALOVIR Tablets 200,400 and 800mg Adley
AXOVIR
Tablets,
Injection
200,400 and 800mg
250 and 800mg vials Samarth
CLOVIRAX DT-Tablets,Cream 5%
200,400 and 800mg
5 gm
Puerhealth
CYCLOVIR Tablets,Cream 5%
200mg
5 gm
Zydus Cadilla
HERPAX
Tablets,
Cream 5%,
Ointment 5%
200,400 and 800mg
5gm
5gm
Microvision
HERPEX DT-Tablets,Cream 5%
200 and 800mg
5 gm
Torrent
LOVIR Tablets 400 and 800mg Eli lilly
OCUVIR
OCUVIR EYE 
OINTMENT
OCUVIR SKIN
DT-Tablets
Eye ointment 3%
Cream 5%
200,400 and 800mg
5 gm
5 gm
FDC
ZOVIRAX
ZOVIRAX 
OPHTHALMIC 
OINTMENT
Tablets, 
Suspension
Ointment 3%
200,400 and 800mg
400 mg/5ml
5 gm
GSK
VIRODERM Ointment 5% 5 gm Emcure
Table 3: Acyclovir products in market37
Carbomer38
 
Structural formula
Figure 4: Acrylic acid monomer unit in carbomer resin
Carbomer  polymers  are  formed  from repeating  units  of  acrylic  acid.  The 
monomer unit is shown above. The polymer chains are crosslinked with allyl sucrose 
or  allylpentaerythritol.  They  contain  between  56%and  68%  of  carboxylic  acid 
(COOH) groups calculated on the dry basis.
Synonyms: Acritamer ; acrylic acid polymer  ; Carbopol ; carboxy poly methylene, 
polyacrylic acid ; Pemulen ; Ultrez
Molecular Weight:  7x105 to 4x109
Description:  Carbomers  are  white-colored,  ‘fluffy’,  acidic,  hygroscopic  powders 
with a slight characteristic odour.
Solubility: soluble in water and, after neutralization, in ethanol (95%) and glycerin.
Viscosity: Carbomers dispersed in water to form acidic colloidal dispersions of low 
viscosity  that,  when neutralized,  produce highly viscous gels.  Carbomer  powders 
should  first  be  dispersed  into  vigorously  stirred  water,  taking  care  to  avoid  the 
formation of indispersible lumps, then neutralized by the addition of a base.
During preparation of gel, the solution should be agitated slowly with a broad 
, paddle like stirrer to avoid air bubbles. Neutralised aqeous gels are more viscous at 
pH 6-11. The viscosity is considerably reduced at pH values less than 3 or greater 
than 12 or presence of strong electrolytes. Gels rapidly lose viscosity. On exposure to 
ultraviolet light, but this can be minimized by the addition of a suitable antioxidant.
Stability and Storage conditions: Carbomers are stable, hygroscopic materials that 
may be heated at temperatures below 1040C for up to 2 hours without affecting their 
thickening efficiency.  However,  exposure to  excessive  temperatures  can result  in 
discoloration and reduced stability. Complete decomposition occurs with heating for 
30 minutes at 260c. Dry powders form of carbomer does not support the growth of 
molds and fungi. But microorganisms grow well in unpreserved aqueous dispersions.
At room temperature,  carbomer dispersions maintain their viscosity during 
storage for prolonged periods. Similarly, dispersion viscosity is maintained, or only 
slightly reduced, at elevated storage temperatures if an antioxidant is included in the 
formulation or if the dispersion is protected from the light.
The  UV  stability  of  carbomer  gels  may  also  be  improved  by  using 
triethanolamine  as  the  neutralizing  base.  Carbomer  powder  should  be  stored  in 
airtight, corrosion-resistant container in a cool, dry place.
Incompatibilities:  Carbomers  are  discolored  by  resorcinol  and  are  incompatible 
with phenol, cationic polymers, strong acids and high levels of electrolytes. Trace 
levels  of  iron  and  other  transition  metals  can  catalytically  degrade  carbomer 
dispersions. Carbomers also form pH dependant complexes with certain polymeric 
exipients.
Applications in pharmaceutical formulation: Carbomers are mainly used in liquid 
or semisolid pharmaceutical formulation as suspending or viscosity-increasing agent.
                                 
Use Concentration (%)
Emulsifying agent
Gelling agent
Suspending agent
Tablet binder
0.1-0.5
0.5-2.0
0.5-1.0
0.5-10.0
Table 4: Uses of carbomers
Regulatory  Acceptance:  Included  in  the  FDA  Inactive  Ingredients  Guide  (oral 
suspensions  and tablets;  ophthalmic,  rectal  and topical  preparations).  Included in 
nonparenteral medicines licensed in Europe. 
                            
Grade of 
Carbopol Acrylic acid cross linked with
Viscosity
Carbopol 931 Penta erythritol 3000-7000cps of a 1%Aqueous dispersion
Carbopol 934
Sucrose 30,500-39,400cps of a 
0.5%
Aqueous dispersion
Carbopol 940
Penta erythritol 40,000-60,000cps of a 
0.5%
Aqueous dispersion
Carbopol 941
Penta erythritol 4000-11,000cps of a 
0.5%
Aqueous dispersion
Carbopol 1342
Co-polymer of acrylic acid 
& long chain allyl methacrylate 
cross linked with allyl ether of 
Penta erythritol
9,500-26,000cps of a 1%
Aqueous dispersion
       
Table 5: Specification of Carbopols
Hydroxy propyl methyl cellulose38
Structural formula
                                   
Figure 5: Structure of Hydroxy propyl methylcellulose
Hydroxypropyl  methyl  cellulose is water soluble non ionic polysaccharide 
polymers.  It  is  available  in  several  grades  that  vary  in  viscosity  and  extent  of 
substitution.  HPMC  defined  in  the  USP  25  specifies  the  substitution  type  by 
appending a four digit number to the non proprietary name: e.g., HPMC 1828. The 
first two digits refer to the approximate percentage content of the methoxy group 
(OCH3). The second two digits refer to the approximate percentage content of the 
hydroxypropoxy group (OCH2CH(OH)CH3).
Chemical Name: Cellulose, 2-hydroxypropyl methyl ether
Synonyms:  Benecel  MHPC;cellulose,  hydroxypropyl  methyl  ether;  HPMC; 
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose.
Molecular weight: 10,000-1,500,000
Description:  HPMC is an odorless and tasteless, white or creamy-white fibrous or 
granular powder.
Solubility : soluble in cold water and insoluble in hot water; practically insoluble in 
chloroform,  ethanol(95%)  and  ether,  but  soluble  in  mixtures  of  ethanol  and 
dichloramethane, mixtures of methanol and  dichloramethane, and mixtures of water 
and ethanol.
Viscosity: Wide ranges of viscosity types are commercially available. To prepare an 
aqueous solution HPMC is dispersed and thoroughly hydrated in about 20-30% of 
the required amount of water. The water should be vigorously stirred and heated to 
80-900c, then the remaining HPMC is added. Cold water should then be added to 
produce the required volume. 
Stability and Storage conditions: HPMC powder is a stable material, although it is 
hygroscopic after drying.  Solutions are stable at  pH 3-11. Increasing temperature 
reduces the viscosity of solutions.  The gel  point  is  50-900C, depending upon the 
grade and concentration of material.
Aqueous solutions are providing good viscosity,  stability during long term 
storage. However, aqueous solutions are liable to microbial spoilage and should be 
preserved with an antimicrobial preservative. HPMC powder should be stored in a 
well-closed container, in a cool, dry place.
Incompatibilities:  HPMC is incompatible with some oxidizing agents. Since it is 
nonionic,  HPMC will  not  complex  with  metallic  salts  or  ionic  organics  to  form 
insoluble precipitates.
Applications in pharmaceutical formulation:  HPMC is widely used in oral and 
topical pharmaceutical formulations. 
 
Use Concentration (%)
Film forming agent
Gelling 
agent(ophthalmic)
Tablet binder
2.0-20.0
0.45-1.0
           2.0-5.0
Table 7:  Uses of Hydroxypropyl methyl cellulose
HPMC is  also  used  as  an  emulsifier,  suspending  agent  and  stabilizing  agent  in 
topical gels  and ointments.  It is also used in the manufacture of capsules,  plastic 
bandages, and as a wetting agent for hard contact lenses.  
Regulatory status:  Accepted as a food additive in Europe.  Included in the FDA 
Inactive  Ingredients  Guide  (ophthalmic  preparations;  oral  capsules,  suspensions, 
syrups  and  tablets;  topical  and  vaginal  preparations).  Included  in  nonparenteral 
medicines licensed in the UK.
Carboxy methyl cellulose-Sodium38
Structural formula
                    Figure 6: Structure of Carboxy methyl cellulose-Sodium
Chemical Name: Cellulose, carboxymethyl ether, sodium salt
Synonyms:  Akucell;  Aquasorb;  Blanose;  cellulose  gum;  CMC  sodium;  E466; 
Finnfix;  SCMC;  sodium  carboxymethyl  cellulose;  sodium  cellulose  glycolate; 
sodium CMC; Tylose CB.
Molecular weight:  90,000-700,000
Description:  Carboxymethylcellulose  sodium occurs  as  a  white  to  almost  white, 
odorless, granular powder.
Solubility:  Practically  insoluble  in  acetone,  ethanol,  ether  and  toluene.  Easily 
dispersed in water at all temperatures, forming clear, colloidal solutions.
Viscosity: It  is  available  in  low,  medium  and  high  viscosity  grades.  Prolonged 
heating at high temperatures will depolymerize the gum and permanently decrease 
the  viscosity.  The  viscosity  of  sodium carboxymethylcellulose  solutions  is  fairly 
stable over a pH range of 4-10. The optimum pH range is neutral.
 
Stability  and  Storage  conditions:  Carboxymethylcellulose  sodium  is  a  stable, 
though hygroscopic material. Under high humidity conditions, it can absorb a large 
quantity (>50%) of water. Solutions exhibit maximum viscosity and stability at pH 
7-9.
Aqueous solutions stored for prolonged periods should contain antimicrobial 
preservative. The bulk material should be stored in a well-closed container in a cool, 
dry place.
Incompatibilities:  Carboxymethylcellulose  sodium is  incompatible  with  strongly 
acidic solutions and with the soluble salts of iron and some other metals, such as 
aluminium, mercury and zinc. Carboxymethylcellulose sodium forms complex with 
gelatin and pectin also with collagen.
Applications in pharmaceutical formulation:  Carboxymethylcellulose sodium is 
widely used in oral and topical formulations, primarily for its viscosity-increasing 
properties.
Use Concentration (%)
Emulsifying agent
Gelling agent
Oral solutions
Tablet binder
Injections
0.25-1.0
3.0-6.0
0.1-1.0
1.0-6.0
0.05-0.75
Table 6: Uses of carboxymethylcellulose sodium
Regulatory status:  Accepted as a food additive in Europe.  Included in the FDA 
Inactive  Ingredients  Guide  (dental  preparations,  inhalations,  intra-articular, 
intradermal,  intra-lesional,  IM and  subcutaneous  injections;  oral  capsules,  drops, 
solutions,  suspensions,  syrups  and  tablets;  topical  and  vaginal  preparations). 
Included in nonparenteral medicines licenced in the UK.
Triethanolamone38
Structural formula
Figure 7: Structure of Triethanolamine
Synonyms  :  Daltogen;  TEA;  Tealan;  triethanolamine;  trihydroxytriethylamine; 
tris(hydroxyl)amine
Chemical Name : 2, 2’, 2’’-Nitrilotriethanol
Molecular weight: 149.19
Description:  clear, colorless to pale yellow- colored viscous liquid having a slight 
ammonical odour.
Solubility: Soluble in chloroform and miscible with acetone, ethanol, methanol and 
water. 
Stability and Storage conditions: Triethanolamine may turn brown on exposure to 
air and light. It should be stored in airtight container protected from light, in a cool, 
dry place.
Incompatibilities: It will react with mineral acids to form crystalline salts and esters 
and also react with copper to form complex salts, discoloration and precipitation can 
take place in the presence of heavy metal salts.
Category: Neutralizing agent, Emulsifying agent.
Regulatory status: Included in the FDA Inactive Ingredients Guide (rectal, topical 
and vaginal preparations). Included in nonparenteral medicines licensed in the UK.
Dimethyl sulfoxide38
Structural formula:             
                                              O
                 | |
                      CH3 – S – CH3 
Synonyms:  Deltan  ;  dimexide  ;  dimethyl  sulfoxide  ;  DMSO ;  kemsol  ;  methyl 
sulfoxide; Rimso-50 ; sulphinylbismethane.
Chemical Name: Sulfinylbismethane
Molecular weigh: 78.13
Description: colorless,  viscous  liquid;  miscible  with  water,  alcohol  and  ether; 
slightly bitter taste; odourless; extremely hygroscopic; absorbing up to 70% of its 
own weight in water with evaluation of heat.
Stability and Storage conditions: DMSO is reasonably stable to heat, temperature 
between 40-600C it has been partially break down, which is indicated by changes 
physical properties. When heated to decomposition and toxic fumes are emitted. It 
should be stored in airtight, light resistance containers. Contact with plastics should 
be avoided.
Applications in Pharmaceutical formulation:  Penetration Enhancer and Solvent, 
which enhances the topical penetration of drugs from the stratum corneum and the 
use of DMSO to improve transdermal deliver has been reported.
Incompatibilities: DMSO can react with oxidizing materials. 
Compatibility Study
                        The drug Acyclovir  and the polymers  namely Carbopol,  
Hydroxypropyl  methyl  cellulose  and  Sodium  Carboxy  methyl  cellulose  were 
analyzed by Fourier Transform Spectrophotometer (FTIR).
The IR spectrums were interpreted and the compatibility of the drug 
with the polymers were confirmed.
S.No Sample Assignments(cm-1)
(O-H)st
(alcoholic)
(C-O-C)st (C=O)St
(O-H)st
(carboxylic)
(C-H)st (N-H)st (C=N)st
1 Acyclovir(ACV)
3307,
(1049,1306)*
1104 1712 ------ 2856 3442 1634
2 Carbopol ------ ------ 1716 3443 2941 ------ ------
3 HPMC
3442,
(1059,1317)*
1117 ------ ------ 2926 ------ ------
4 Sodium CMC ------ 1064 1638 3439 2926 ------ ------
5 ACV+ Carbopol
3300,
(1050,1304)*
1104 1713 3185
2927,
2862
3442 1634
6 ACV+HPMC 3305,1307* 1104 1712 ------ 2866 3442 1633
7 ACV+ Sodium CMC
3301,1306
* 1104 1713 3185 2860 3442 1633
st – stretching,   *Primary alcohol
Table 8: Interpretation of IR Spectrums39
FIGUIRE: 8 IR SPECTRUM OF ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sam=Acyclovir.sp  
Sam=Acyclovir.pk 
 SAM_AC~2.SP  3601  4000.00  400.00  3.52  99.48  4.00  %T  5  1.00 
 REF 4000 98.80 2000 95.59 600 
3442.30  5.89   3307.26  7.01   3187.15  7.73   2923.48  27.28  2856.34  25.59   
2702.41  21.48  1712.29  5.98   1634.14  3.52   1537.59  21.36  1482.02  18.45   
1389.74  16.53  1352.75  25.12  1306.17  39.24  1217.91  44.25  1181.28  28.83   
1104.51  11.46  1049.25  21.93  899.57   36.74  775.13   43.11  751.98   40.38   
681.10   36.73  623.02   29.59  460.06   87.28   
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FIGUIRE: 9 IR SPECTRUM OF CARBOPOL
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =Carbopol.sp  
Sample =Carbopol.pk 
 SAMPLE~1.SP  3601  4000.00  400.00  3.22  100.00  4.00  %T  5  1.00 
 REF 4000 99.56 2000 87.05 600 3443.48  10.48   2941.36  20.11   2626.38  49.11   1716.29  3.22    1450.31  36.98    
1410.04  40.05   1250.60  19.44   1176.21  24.53   917.52   77.19   801.28   57.06    
616.73   65.44   525.14   72.61    
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      FIGURE: 10 IR SPECTRUM OF HYDROXY PROPYL 
METHYLCELLULOSE
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =HPMC.sp  
Sample =HPMC.pk 
 
SAMPLE~3.SP  3601  4000.00  400.00  7.94  100.00  4.00  %T  5  0.50 
 
REF 4000 82.69 2000 79.65 600 
3442.94  7.94    2926.41  32.77   2598.78  81.72   2363.49  62.60   2337.71  66.07    
2071.21  74.41   1647.11  23.43   1464.67  35.67   1388.57  31.97   1317.66  41.73    
1117.56  20.61   1059.55  19.80   944.63   44.15   662.59   48.08   614.15   47.77    
576.69   49.82    
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      FIGURE: 11 IR SPECTRUM OF SODIUM CARBOXY 
METHYLCELLULOSE
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =CMC-Sodium.sp  
Sample =CMC-Sodium.pk 
 
SAMPLE~2.SP  3601  4000.00  400.00  3.17  98.47  4.00  %T  5  0.50 
 
REF 4000 98.30 2000 96.72 600 
3439.02  3.17   2926.03  49.71  2509.08  97.31  2361.26  69.22  2130.88  89.65   
1638.20  10.06  1421.02  28.95  1327.92  48.04  1271.18  66.67  1113.33  27.63   
1064.73  25.24  667.90   43.02  612.68   42.68   
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FIGURE: 12 IR SPECTRUM OF CARBOPOL + ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sam=Acyclovir+Carbopol.sp  
Sam=Acyclovir+Carbopol.pk 
 
SAM_AC~3.SP  3601  4000.00  400.00  3.43  99.81  4.00  %T  5  1.00 
 
REF 4000 99.67 2000 99.55 600 
3519.84  18.13  3442.73  10.27  3300.51  10.56  3185.69  9.34   2927.07  23.65   
2862.82  25.35  2702.60  25.40  2090.01  95.90  1713.13  3.43   1634.77  6.33    
1538.30  42.65  1480.85  33.58  1391.49  26.18  1351.68  33.95  1304.04  39.29   
1220.24  34.30  1181.26  26.14  1104.87  21.07  1050.14  38.22  899.83   51.27   
776.98   55.13  754.78   56.61  680.80   57.52  622.76   44.89   
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FIGURE: 13 IR SPECTRUM OF HPMC + ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =HPMC +Acyclovir.sp  
Sample =HPMC +Acyclovir.pk 
 
SA2AFD~1.SP  3601  4000.00  400.00  3.64  99.57  4.00  %T  5  1.00 
 
REF 4000 99.27 2000 96.12 600 
3519.84  14.97  3442.83  7.08   3305.10  7.99   3186.39  7.97   2866.63  22.80   
2707.55  22.08  2365.71  52.98  1712.04  4.60   1633.75  3.64   1537.21  21.54   
1482.00  15.17  1389.51  13.45  1352.19  19.86  1307.05  30.42  1217.15  27.93   
1181.24  17.82  1104.35  6.38   900.44   29.67  752.58   42.82  680.74   37.28   
623.18   28.90   
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FIGUIRE: 9 IR SPECTRUM OF CARBOPOL
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =Carbopol.sp  
Sample =Carbopol.pk 
 SAMPLE~1.SP  3601  4000.00  400.00  3.22  100.00  4.00  %T  5  1.00 
 REF 4000 99.56 2000 87.05 600 3443.48  10.48   2941.36  20.11   2626.38  49.11   1716.29  3.22    1450.31  36.98    
1410.04  40.05   1250.60  19.44   1176.21  24.53   917.52   77.19   801.28   57.06    
616.73   65.44   525.14   72.61    
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   FIGURE: 10 IR SPECTRUM OF HYDROXY PROPYL METHYLCELLULOSE
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =HPMC.sp  
Sample =HPMC.pk 
 
SAMPLE~3.SP  3601  4000.00  400.00  7.94  100.00  4.00  %T  5  0.50 
 
REF 4000 82.69 2000 79.65 600 
3442.94  7.94    2926.41  32.77   2598.78  81.72   2363.49  62.60   2337.71  66.07    
2071.21  74.41   1647.11  23.43   1464.67  35.67   1388.57  31.97   1317.66  41.73    
1117.56  20.61   1059.55  19.80   944.63   44.15   662.59   48.08   614.15   47.77    
576.69   49.82    
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FIGURE: 11 IR SPECTRUM OF SODIUM CARBOXY METHYLCELLULOSE
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =CMC-Sodium.sp  
Sample =CMC-Sodium.pk 
 
SAMPLE~2.SP  3601  4000.00  400.00  3.17  98.47  4.00  %T  5  0.50 
 
REF 4000 98.30 2000 96.72 600 
3439.02  3.17   2926.03  49.71  2509.08  97.31  2361.26  69.22  2130.88  89.65   
1638.20  10.06  1421.02  28.95  1327.92  48.04  1271.18  66.67  1113.33  27.63   
1064.73  25.24  667.90   43.02  612.68   42.68   
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FIGURE: 12 IR SPECTRUM OF CARBOPOL + ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sam=Acyclovir+Carbopol.sp  
Sam=Acyclovir+Carbopol.pk 
 
SAM_AC~3.SP  3601  4000.00  400.00  3.43  99.81  4.00  %T  5  1.00 
 
REF 4000 99.67 2000 99.55 600 
3519.84  18.13  3442.73  10.27  3300.51  10.56  3185.69  9.34   2927.07  23.65   
2862.82  25.35  2702.60  25.40  2090.01  95.90  1713.13  3.43   1634.77  6.33    
1538.30  42.65  1480.85  33.58  1391.49  26.18  1351.68  33.95  1304.04  39.29   
1220.24  34.30  1181.26  26.14  1104.87  21.07  1050.14  38.22  899.83   51.27   
776.98   55.13  754.78   56.61  680.80   57.52  622.76   44.89   
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FIGURE: 13 IR SPECTRUM OF HPMC + ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =HPMC +Acyclovir.sp  
Sample =HPMC +Acyclovir.pk 
 
SA2AFD~1.SP  3601  4000.00  400.00  3.64  99.57  4.00  %T  5  1.00 
 
REF 4000 99.27 2000 96.12 600 
3519.84  14.97  3442.83  7.08   3305.10  7.99   3186.39  7.97   2866.63  22.80   
2707.55  22.08  2365.71  52.98  1712.04  4.60   1633.75  3.64   1537.21  21.54   
1482.00  15.17  1389.51  13.45  1352.19  19.86  1307.05  30.42  1217.15  27.93   
1181.24  17.82  1104.35  6.38   900.44   29.67  752.58   42.82  680.74   37.28   
623.18   28.90   
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FIGURE: 14 IR SPECTRUM OF SODIUM CMC + ACYCLOVIR
 
FTIR SPECTRUM 
ACIC 
St.Joseph's College ( Autonomous ) 
Trichy-2 
Spectrum Name: Sample =CMC+Acyclovir.sp  
Sample =CMC+Acyclovir.pk 
 
SAFB60~1.SP  3601  4000.00  400.00  3.54  99.61  4.00  %T  5  1.00 
 
REF 4000 99.26 2000 96.55 600 
3520.87  18.21  3442.82  9.49   3301.35  8.74   3185.69  7.62   2860.31  21.99   
2706.76  18.51  1713.05  5.35   1633.47  3.54   1537.24  21.58  1481.49  16.81   
1390.41  15.18  1351.81  21.15  1306.91  33.25  1216.80  38.09  1179.96  22.58   
1103.97  8.93   899.58   33.26  751.24   38.32  680.98   35.42  622.47   28.82   
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EXPERIMENTAL WORK
S.NO Materials Source
1 Acyclovir Microlabs, Hosur
2 Carbopol-934 Kemphasol, Mumbai
3 Carbopol-940 Kemphasol, Mumbai
4 Hydroxy propyl methyl cellulose HIMEDIA LBS, Mumbai
5 Carboxy methyl cellulose-sodium Kemphasol, Mumbai
6 Propyl paraben NATIONAL CHEMICALS
7 Methyl paraben NATIONAL CHEMICALS
8 Dimethyl sulfoxide SUVIDHINATH LABS, BARODA
9 Triethanolamine REACHEM LABS, CHENNAI
10 0.1M Hydrochloric acid --------
11 Cellophane membrane --------
Table 9: Materials used in Research work
Preparation of 0.1M Hydrochloric acid40
Solution  of  0.1M  Hydrochloric  acid  was  prepared  by  diluting  8.5  ml  of 
Hydrochloric acid to 1000ml with water.
S.NO Instruments and Equipments Make
1 Remi stirrer REMI Equipments, Mumbai
2 UV-Spectrophotometer SHIMADZU UV-1700, Japan
3 pH meter ELICO, LI120
4 Digital Balance Sartorius, Mumbai
5 Heating plate Tempo Equipments, Mumbai
6 Viscometer Brookfield
7 Oven Tempo Equipments, Mumbai
8 Refrigerator ALLWYN
9 Diffusion cell -------
10 Magnetic stirrer REMI Equipments, Mumbai
11 Remi Centrifuge REMI Equipments, Mumbai
12 Environment Test 
Chamber HECO
             Table 10: Instruments and Equipments used in Research work
FORMULATION OF GELS 
Acyclovir gels were formulated using different polymers like Carbopol 934, 
Carbopol  940,  Hydroxy  propyl  methyl  cellulose  and  Sodium  Carboxy  methyl 
cellulose. Different concentrations of polymer were used in the formulation of gels. 
The  concentrations  chose  varied  with  the  polymer  used.  After  initial  trials,  the 
concentrations  that  gave  products  of  good  consistency  were  selected  for  the 
formulation.  The  concentration  of  drug  taken  in  all  the  formulation  remained 
constant.
Table 11 to 14 gives the different  concentrations  of polymers  used in the 
formulation.
            
Preparation of Carbopol- 934 gels
Ingredients Formula for 100gms
A1(gms) A2(gms) A3(gms)
Acyclovir 1.0 1.0 1.0
Carbopol-934 0.5 1.0 1.5
Triethanolamine 0.5 0.5 0.5
Purified water 98 97.5 97
Methyl paraben 0.002 0.002 0.002
Table 11: Formulations with varying Carbopol-934 concentrations
      
 Procedure
  1. Accurately weighed quantity of Acyclovir was dispersed in purified water with 
      constant stirring and the drug solution was heated to 500C. 
 2. Methyl paraben was added as a preservative.
 3. The carbopol-934 was added to the solution under stirring while temperature  
    Was  maintained at 500 C.
 4. The dispersion of gelling agent was neutralized by addition of triethanolamine 
    solution to attain the neutral pH . Stirred slowly till a clear gel was obtained.
Preparation of Carbopol- 940 gels
Ingredients Formula for 100gms
B1(gms) B2(gms) B3(gms)
Acyclovir 1.0 1.0 1.0
Carbopol-940 0.5 1.0 1.5
Triethanolamine 0.5 0.5 0.5
Purified water 98 97.5 97
Methyl paraben 0.002 0.002 0.002
Table 12: Formulations with varying Carbopol-940 concentrations
Procedure
1.  Accurately weighed quantity of Acyclovir was dispersed in purified water  
        with  constant stirring and the drug solution was heated to 500 C. 
 2.  Methyl paraben was added as a preservative.
 3. The carbopol-940 was added to the solution under stirring while temperature was 
     maintained at 500 C.
 4. The dispersion of gelling agent was neutralized by addition of triethanolamine 
    solution to attain the neutral pH. Stirred slowly till a clear gel was obtained.
Preparation of Hydroxy propyl methyl cellulose gels
Ingredients Formula for 100gms
C1(gms) C2(gms) C3(gms) C4(gms)
Acyclovir 1.0 1.0 1.0 1.0
Hydroxy propyl 
methyl cellulose
1.0 1.5 3.0 4.0
Purified water 98 97.5 96 95
Methyl paraben 0.002 0.002 0.002   0.002
Table 13: Formulations with varying Hydroxy propyl methyl cellulose 
concentrations
Procedure
1. Accurately weighed quantity of Acyclovir was dispersed in purified water with  
    constant stirring and the drug solution was heated to 500 C. 
2. The solution was maintained at 500 C, HPMC was gradually added to the 
    Solution  under stirring until a thick viscous gel was formed.
3. Methyl paraben was added finally to the preparation as a preservative.
4. Formulation was allowed to settle down to room temperature
Preparation of Sodium Carboxy methyl cellulose gels
        Table No 14: Formulations with varying Sodium carboxy methyl cellulose 
concentrations
Ingredients Formula for 100gms
D1(gms) D2(gms) D3(gms)
Acyclovir 1.0 1.0 1.0
Sodium  Carboxy  methyl 
cellulose
2.0 3.0 4.0
Purified water 97 96 95
Methyl paraben 0.002 0.002 0.002
Procedure
1. Accurately weighed quantity of Acyclovir was dispersed in purified water with  
    Constant stirring. 
2. Sodium Carboxy methyl cellulose was added under stirring to the above  
    solution.
3. Methyl paraben was added to the dispersion under stirring as a preservative.
4. The dispersion was allowed to stand for complete hydration of Sodium CMC. 
    Finally the weight was adjusted to 100gm by adding purified water. 
EVALUATION OF GELS
The prepared gels were proposed to be evaluated for Drug content, pH, Viscosity, 
Extrudability,  Spreadability,  In  vitro  release  characteristic  and  the  selected  gel 
formulation subjected for Stability and In-vivo study by using Albino Rabbits.
Standard curve of Acyclovir
100 mg of accurately weighed Acyclovir was dissolved in little amount of 
0.1M  hydrochloric  acid  and  made  up  to  required  volume  100  ml  with  0.1M 
hydrochloric acid41. So that each ml of stock solution required concentration of 5, 10, 
15, 20, 25, 30, 35 and 40 µg/ml was made up with 0.1M hydrochloric acid. The 
absorbance  of  the  dilute  sample  was  measured  spectrophotometrically  at  255nm 
using 0.1M hydrochloric  acid in UV- spectrophotometer42.  The standard plot was 
made with concentration (µg /ml) on X axis and Absorbance on Y axis.
                         Table 15: Standard curve of Acyclovir
S.No Concentration 
(µg/ml)
Absorbance at 
255nm
1 5 0.399
2 10 0.647
3 15 0.896
4 20 1.119
5 25 1.347
6 30 1.513
7 35 1.726
8 40 1.947
                                                                      Average of three readings 
        r=0.9932             a=0.1366                b=0.0486   
Figure 15: Standard curve of Acyclovir
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Estimation of Drug content
1gm of Acyclovir gel was dissolved in sufficient quantity of 0.1M hydrochloric 
acid to get the clear solution, volume was made up to 100ml with 0.1M hydrochloric 
acid. 1ml of the solution was diluted to 10ml with 0.1M hydrochloric acid solution. 
Absorbance was measured at 255nm using UV spectrophotometer. 
The amount of Acyclovir was determined from the standard calibration curve 
and the percentage drug content  in different formulations  was calculated.  Results 
were tabulated as follows
Formulation
Drug content 
(mg)
Drug content 
(%)
A2 10.172 101.72
B2 9.81 98.1
C3 9.78 97.8
D2 9.69 96.9
              Average of three readings
Table 16: Drug content in the gel formulations
pH Measurements
pH measurements of the gel were carried out using a digital pH meter by dipping 
the glass electrode completely into the gel system so as to cover the electrode. The 
results were tabulated as follows
Formulation pH
A2 6.9
B2 7.2
C3 7.1
D2 6.8
                                                Average of three    readings
Table 17: pH of gel formulations
Determination of viscosity
Viscosities of the gels were determined by using Brookfield Viscometer (model- 
RVTP).Spindle type, RV-7 at 20 rpm. 100gm of the gel was taken in a beaker and 
the spindle was dipped in it and rotated for about 5 minutes and then reading was 
taken. The results were shown in Table 18
Formulation Viscosity in cps
A2 43,000
B2 41,000
C3 36,000
D2 51,000
              Average of three readings
Table 18: Viscosity of gel formulations
Extrudability
It is useful empirical test to measure the force required to extrude the material 
from the tube. The formulations were  filled in a collapsible metal tubes with a nasal 
tip  of   5mm  opening  tube  extrudability  was  then  determined  by  measuring  the 
amount  of  gel,  extruded  the  tip  when  a  pressure  was  applied  on  tube  gel.  The 
extrudability of the formulation was checked and the results were tabulated.
                
Formulation Extrudability
A2 +++
B2 +++
C3 +
D2 ++
          +++Excellent, ++Good, +Not satisfactory
Table 19: Extrudability of gel formulations
Determination of spreadability
One of the criteria  for a gel  meet  ideal  quality is  that  it  should possess good 
spreadability. About 1 gm of gel formulation was weighed and kept at the center of 
the glass plate of standard dimensions (10x10cm) and another glass plate placed over 
it carefully, that the gel was sandwiched between the two slides. 2 kg weight was 
placed at the center of the plate (avoid sliding of the plate). The diameter of the gel 
in cms, after 30 minutes was measured and the results were tabulated in Table 20
Formulation
Time taken 
(minutes)
Spreadability (cm)
A2 30 8.0
B2 30 7.8
C3 30 7.4
D2 30 7.7
       Average of three readings
Table 20: Spreadability of gel formulations
In vitro Drug release pattern of Acyclovir gels
The In vitro release of Acyclovir from the gel formulation was studied by open 
ended cylinder method. This diffusion cell apparatus consists of a glass tube with an 
inner  diameter  of  2.5 cm,  open at  the both ends.  One end of the tube tied  with 
Cellophane membrane, which serves as a donar compartment.
1 gm of Acyclovir  gel was taken in this  compartment  and placed in a beaker 
containing 200ml of 0.1M Hydrochloric acid stirring at moderate speed, maintaing 
the temperature at 37±10C. Periodically 5ml of samples were withdrawn and after 
each  withdrawal  using  0.1M  Hydrochloric  acid  was  replaced  into  the  diffusion 
medium to maintain the sink condition through out the experimentation. Then the 
samples were assayed by spectrophotometrically at 255nm in UV-Spectrophotometer 
using 0.1M Hydrochloric acid as blank.
               Table 21: Drug release profile of Formulation A2 (1% Carbopol-934)
Time
(minutes)
Absorbance at
255nm
Concentration
(µg/ml)
Amount of drug 
release(mg)
Percentage
drug release*
30 0.205 1.407 0.281 2.81
60 0.461 6.674 1.334 13.34
90 0.592 9.370 1.874 18.74
120 0.705 11.695 2.339 23.39
150 0.747 12.559 2.511 25.11
180 0.763 12.880 2.577 25.77
210 0.884 15.378 3.075 30.75
240 1.074 19.286 3.857 38.57
270 1.143 20.707 4.141 41.41
300 1.237 22.641 4.528 45.28
360 1.516 28.382 5.672 56.72
420 1.610 30.316 6.063 60.63
480 1.714 32.456 6.491 64.91
                                         *Average of three  readings
         Table 22: Drug release profile of Formulation B2 (1% Carbopol-940)
Time
(minutes)
Absorbance
at
255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.186 1.016 0.203 2.03
60 0.365 4.699 0.934 9.34
90 0.481 7.086 1.417 14.17
120 0.520 7.888 1.577 15.77
150 0.617 9.884 1.976 19.76
180 0.676 11.098 2.219 22.19
210 0.747 12.559 2.511 25.11
240 0.843 14.534 2.906 29.06
270 0.906 15.831 3.166 31.66
300 0.963 17.004 3.400 34.00
360 1.184 21.551 4.310 43.10
420 1.243 22.765 4.553 45.53
480 1.394 25.872 5.147 51.47
       *Average of three  readings
      Table 23:  Drug release profile of Formulation C3 (3% Hydroxypropyl 
                         methyl cellulose)
Time
(minutes)
Absorbance at
255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.162 0.522 0.104 1.04
60 0.312 3.609 0.721 7.21
90 0.396 5.337 1.067 10.67
120 0.443 6.304 1.260 12.60
150 0.503 7.539 1.507 15.07
180 0.532 8.135 1.627 16.27
210 0.598 9.493 1.898 18.98
240 0.687 11.325 2.265 22.65
270 0.763 12.883 2.577 25.77
300 0/846 14.596 2.919 29.19
360 0.904 15.790 3.158 31.58
420 1.116 20.152 4.030 40.30
480 1.207 22.024 4.404 44.04
                                                                                      *Average of three Readings
     Table 24: Drug release profile of Formulation D2 (3% Sodium     
                       Carboxy methyl cellulose)
Time
(minutes)
Absorbance
at 255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.136 ------ ------ ------
60 0.269 2.724 0.544 5.44
90 0.313 3.629 0.725 7.25
120 0.361 4.617 0.923 9.23
150 0.414 5.707 1.141 11.41
180 0.474 6.942 1.388 13.88
210 0.543 8.362 1.672 16.72
240 0.613 9.802 1.960 19.60
270 0.686 11.304 2.260 22.60
300 0.734 12.292 2.458 24.58
360 0.816 13.979 2.795 27.95
420 0.903 15.769 3.153 31.53
480 0.976 17.271 3.454 34.54
   *Average of three Readings
      In vitro drug release of gel formulations with Dimethyl sulfoxide (DMSO) as 
      a permeation enhancer.
     Table 25: Drug release profile of Formulation A2 with Dimethyl  
                             sulfoxide
*
Time
(minutes)
Absorbance
At 255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.243 2.251 0.450 4.50
60 0.514 7.765 1.553 15.53
90 0.646 10.481 2.096 20.96
120 0.761 12.847 2.569 25.69
150 0.804 13.732 2.746 27.46
180 0.823 14.123 2.824 28.24
210 0.946 16.654 3.330 33.34
240 1.141 20.666 4.133 41.33
270 1.276 23.444 4.688 46.88
300 1.407 26.139 5.222 52.22
360 1.651 31.160 6.232 62.32
420 1.798 34.185 6.837 68.37
480 1.907 36.427 7.285 72.85
*Average of three Readings
 Table 26: Drug release profile of Formulation B2 with Dimethyl sulfoxide 
Time
(minutes)
Absorbance
at
255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.214 1.592 0.318 3.18
60 0.398 5.378 1.075 10.75
90 0.541 8.320 1.664 16.64
120 0.634 10.234 2.046 20.46
150 0.703 11.654 2.330 23.30
180 0.721 12.024 2.404 24.04
210 0.911 15.934 3.186 31.86
240 0.984 17.436 3.487 34.87
270 1.073 19.267 3.853 38.53
300 1.124 20.316 4.063 40.63
360 1.343 24.823 4.964 49.64
420 1.461 27.251 5.450 54.50
480 1.605 30.213 6.042 60.42
                                                                                               *Average of three Readings
 Table 27: Drug release profile of Formulation C3 with Dimethyl sulfoxide
Time
(minutes)
Absorbance
At 255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.201 1.325 0.265 2.65
60 0.396 5.337 1.067 10.67
90 0.474 6.942 1.388 13.88
120 0.523 7.950 1.590 15.90
150 0.614 9.823 1.964 19.64
180 0.692 11.427 2.285 22.85
210 0.746 12.534 2.507 25.07
240 0.816 13.979 2.795 27.95
270 0.932 16.366 3.273 32.73
300 1.003 17.827 3.565 35.65
360 1.104 19.905 3.981 39.81
420 1.271 23.341 4.668 46.68
480 1.394 25.872 5.174 51.74
*Average of three Readings
          Table 28: Drug release profile of Formulation D2 with Dimethyl sulfoxide
Time
(minutes)
Absorbance at
255nm
Concentration
(µg/ml)
Amount of 
drug release
(mg)
Percentage 
drug release*
30 0.194 1.181 0.236 2.36
60 0.304 3.444 0.688 6.88
90 0.396 5.337 1.067 10.67
120 0.464 6.736 1.347 13.47
150 0.497 7.415 1.483 14.83
180 0.583 9.185 1.837 18.37
210 0.612 9.781 1.956 19.56
240 0.698 11.551 2.310 23.10
270 0.761 12.847 2.569 25.69
300 0.864 14.967 2.993 29.93
360 0.938 16.489 3.297 32.97
420 1.042 18.629 3.725 37.25
480 1.163 21.119 4.223 42.23
   *Average of three Readings
                                                       Table 29
      Compare the percentage release of Acyclovir from gel formulations with      
      and without Dimethyl sulfoxide (DMSO).
Time
(Mins)
Gel Formulations Gel Formulations with DMSO
A2 B2 C3 D2 A2 B2 C3 D2
30 2.81 2.03 1.04 ----- 4.50 3.18 2.65 2.36
60 13.34 9.34 7.21 5.44 15.53 10.75 10.67 6.88
90 18.74 14.17 10.67 7.25 20.96 16.64 13.88 10.67
120 23.39 15.77 12.60 9.23 25.69 20.46 15.90 13.47
150 25.11 19.76 15.07 11.41 27.46 23.30 19.64 14.83
180 25.77 22.19 16.27 13.88 28.24 24.04 22.85 18.37
210 30.75 25.11 18.98 16.72 33.34 31.86 25.07 19.56
240 38.57 29.06 22.65 19.60 41.33 34.87 27.95 23.10
270 41.41 31.66 25.77 22.60 46.88 38.53 32.73 25.69
300 45.28 34.00 29.19 24.58 52.22 40.63 35.65 29.93
360 56.72 43.10 31.58 27.95 62.32 49.64 39.81 32.97
420 60.63 45.53 40.30 31.53 68.37 54.50 46.68 37.25
480 64.91 51.47 44.04 34.54 72.85 60.42 51.74 42.23
*Average of 
three Readings
Figure 16: In vitro release profile of Acyclovir from 1% Carbopol – 934 
gel
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Figure 17: In vitro release profile of Acyclovir from 1% Carbopol – 940 
gel
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Figure 18: In vitro release profile of Acyclovir from 3% Hydroxy propyl 
methyl cellulose gel
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Figure 19: In vitro release profile of Acyclovir from 3% Sodium 
carboxy methyl cellulose gel
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Figure 20: Comparative in vitro release profile of Acyclovir from 1% 
Carbopol -934 gel formulation with permeation enhancer
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Figure 21: Comparative in vitro release profile of Acyclovir from 1% 
Carbopol -940 gel formulation with permeation enhancer
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Figure 22: Comparative in vitro release profile of Acyclovir from 3% 
Hydroxy propyl methyl cellulose gel formulation with permeation 
enhancer
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Figure 23: Comparative in vitro release profile of Acyclovir from 3% 
sodium carboxy methyl cellulose formulation with permeation enhancer
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Figure 24: Comparative in vitro release profile of Acyclovir from 
different gel formulations
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Figure 25: Comparative in vitro release profile of Acyclovir from 
different gel formulations ith permeation enhancer
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Stability studies of the selected gel formulation 43
The assessment procedure for the stability of a pharmaceutical product lies in 
the  capability  of  a  formulation  to  retain  its  physical,  chemical  and  therapeutic 
specifications.  A  general  methodology  for  predicting  the  stability  is  accelerated 
stability analysis in which the materials are subjected to elevated temperatures. This 
does not hold good for gels, as they melt at higher temperature conditions.
Thus  the  most  commonly  applied  temperatures  are  refrigeration  (4-50C), 
room temperature  (25-300C) and 37±50C. Then the samples  were checked at  the 
regular intervals of 1, 2 and 3 months. Different parameters considered for analysis 
are shown below.
Physical parameters
1. Visual Appearance 
2. pH
3. Viscosity
4. Extrudability
5. Phase separation
6. Leakage
7. Nature
Chemical parameters
 Drug content analysis of active ingredients
Method
The selected formulation was filled into aluminium collapsible tubes and stored at
a. Room temperature
b. 37±50C
c. 4-50C
The  gel  formulation  was  stored  for  a  period  of  three  months.  Samples  were 
withdrawn at monthly intervals for a period of three months and assessed for the 
drug content. At the end of third month they were evaluated for physical parameter 
and integrity of the product.
1. Physical evaluation of gels
The physical parameters considered for the evaluation were Visual appearance, 
Nature of the product, pH, Viscosity, Leak, Phase separation and Extrudability.
2. Chemical evaluation
The drug content of the formulation was estimated by withdrawing samples from 
different corners of the tube. The samples were mixed together and 1gm was taken 
for the assay. The estimation of drug content was carried out as per the procedure.
              
                 Table 30: Physical evaluation of formulation A2 (1% Carbopol-934)
Parameters Room Temperature 37±50C 4-50C
Visual appearance
      Initial 
      Final
Transparent
Transparent
Transparent
Transparent
Transparent
Transparent
pH                       
      Initial 
      Final
6.9
7.1
6.9
7.0
6.9
6.9
Viscosity (cps) 
       Initial 
       Final
43,000
43,000
43,000
43,500
43,000
43,000
Extrudability 
       Initial 
       Final
+++
+++
+++
+++
+++
+++
Phase separation Not found Not found Not found
Leakage Not found Not found Not found
Nature 
      Initial 
      Final
Smooth
Smooth
Smooth
Smooth
Smooth
Smooth
+++Excellent.
Chemical evaluation
The drug content of the formulation was estimated over a period of 3 months. The 
results were tabulated as follows. 
                                             
Table 31: Drug content of formulation A2 (1% Carbopol-934)
  
  Each reading represents the average of three determinations
Skin irritation test44
The primary skin irritation test was performed on healthy albino rabbits, weighing 
between 2.0-3.5 kg. The gel formulation film was prepared and used as test patches, 
while adhesive tape (USP) was used as control. The test was conducted on unbraided 
skin of the rabbits. The control and test patches were placed on the left and right 
dorsal surfaces of the rabbits respectively. The patches were removed after 24 hours 
with the help of alcohol swab and the skin was examined for erythema and edema45, 
and its shown in figure No.26 & 27.
Storage condition Withdrawal period (monthly)
0 1 2 3
4-50C 101.72 101.54 100.04 99.36
Room Temperature 101.72 100.86 99.48 98.93
37±50C 101.72 100.55 99.08 98.24
                 Figure 26: Initial skin appearance for irritation test
        Figure 27: Skin appearance after 24 hrs for irritation test
In vivo studies of the selected gel formulation
Selection of Animal model
Rabbits were chosen as an animal model for the In vivo evaluation because 
rabbits had the advantage of ease of safety handling and experimentation.
Experiment
In vivo studies were performed by using Albino Rabbits, weighing from 1.5 
to 2.0 kg selected for this study and they were fed with vegetables and water. The 
animals were divided into two groups, each group containing six animals.
The groups under treatment were designed as follows,
                 Group - I:  Marketed ACIVIR Cream as Standard
                 Group - II:  Selected gel formulation as Test.
The standard and test sample were administered at the unbraided area of the 
skin. After administration, exactly 1 ml of blood samples were collected from the 
marginal ear veins of rabbits using sterile butterfly needles and syringes at one hour 
intervals from zero hour to a period of two biological half lives of the drug and then 
transferred into sterile vials containing 1ml of sterile anticoagulant solution (10 mg 
of sodium citrate in 100 ml of sterile water). Then the plasma was separated from the 
blood by centrifugation  at  3000rpm in Remi centrifuge  for  10 minutes  and then 
supernatant plasma was collected. The plasma was transferred to screw capped vials 
and kept in the refrigerator till the samples were analyzed.
  
Figure 28
Blood sampling for In vivo studies of Acyclovir topical gel
Determination of plasma drug concentration
The  plasma  levels  of  drug  were  determined  by  Shimadzu  UV-
Spectrophotometer.  The each sample  was diluted  with equal  quantity  of  distilled 
water.  Then  the  prepared  solutions  were  analyzed  by  UV-Spectrophotometer  at 
255nm by using distilled water as blank. The absorbances of drug were enlighted in 
Table 32 & 33. From the absorbance the drug concentration in blood samples at 
different time intervals both standard and test group animals were calculated from 
the standard graph and the results are given in the Table 34.
Pharmacokinetic parameters46
From all the above data obtained, Area Under Curve (AUC) was plotted in 
graph taking Time (in hours) on X-axis and plasma drug concentration (µg/ml) in Y-
axis. The AUC was determined by using Trapezoidal rule.
AUC =( 1/2)(C1+C2)(t2-t1)+(1/2) (C2+C3)(t3-t2)+………+(1/2) (Cn-1+Cn)(tn- tn-
1) 
Where,   C = Drug concentration
             t = Time
Elimination rate constant (Ke)
 It is calculated by the following equation Ke = 0.693/t/2
Elimination half life (t/2)
The (t/2) values were obtained by the extrapolation of Time Vs plasma concentration 
curve’
Peak plasma concentration (Cmax)
Cmax was obtained from the Time Vs Plasma concentration curve.
tmax
      tmax was obtained from the Time Vs Plasma concentration curve.
Relative Bioavailability
The relative bioavailability of drug was determined by using the following formula
Relative Bioavailability =  Area Under Curve  for Test
                                              Area Under Curve for standard
Absorption rate constant (Ka)
The  (Ka) values  were  obtained  by  the  extrapolation  of  Time  Vs  log 
concentration in semilogrthmic curve by Residual (or) Feathering method.
The above all pharmacokinetic parameters were shown in Table 34
                                           
      Table 32
    
   Plasma drug concentration at different time intervals for Standard   
       (ACIVIR cream)
Time
(hours)
Absorbance at
255nm Concentration*(µg/ml)
AUC
(µg hr/ml)
0 0 0 2.154
1 0.346 4.308 10.666
2 0.964 17.024 19.493
3 1.204 21.962 17.970
4 0.816 13.979 10.851
5 0.512 7.724 7.322
6 0.473 6.921 -----
                                                                *Average of three readings
Table 33
          Plasma drug concentration at different time intervals for Test-A2   
         (1%Carbopol gel formulation)
Time
(hours)
Absorbance at
255nm Concentration(µg/ml)
AUC
(µg hr/ml)
0 0 0
1 0.494 7.353 3.676
2 1.074 19.288 13.320
3 1.319 24.329 21.778
4 1.102 19.864 22.096
5 0.974 17.230 18.547
6 0.721 12.024 14.627
  *Average of three readings
Table 34
    Pharmacokinetic Parameters for Standard (ACIVIR Cream) and Test     
    (Acyclovir gel)
S.No PharmacokineticParameters Units Standard Test
1 AUC (µg hr/ml) 98.032 146.322
2 Relative Bioavailability ------------ --------- 1.492
3 Cmax (µg/ml) 21.962 24.329
4 tmax Hours 3 3
5 Ke (Elimination rate constant) Hour-1 0.234 0.230
6 t/2   (Elimination half life) Hours 2.96 3.01
7 Ka (Absorption rate constant) Hour-1 0.621 0.575
Figure 29: Area Under curve (AUC) of Acyclovir for Standard 
(ACIVIR cream)
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Figure 30: Area Under curve (AUC) of Acyclovir for Test (Acyclovir 
gel)
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Figure 31: Comparative Area Under curve (AUC) of Acyclovir for Test 
and Standard
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Figure 32
Figure 33
RESULTS AND DISCUSSION
Compatibility Study
With reference to the IR-spectrum, the drug Acyclovir was compatible with 
all  the  polymers  namely  Carbopol,  Hydroxypropyl  methyl  cellulose  and  Sodium 
carboxy methyl cellulose were used in the gel formulation.
Formulation of Acyclovir topical gels using various gelling agents
Gel formulations of acyclovir were prepared using different polymers namely 
Carbopol-934, Carbopol-940, Hydroxypropyl methyl cellulose and Sodium carboxy 
methyl cellulose as per the procedure.
Carbopol-934 as a gelling agent
Formulations with formula A1 (0.5%Carbopol-934), A2 (1.0%Carbopol-934) 
and  A3 (1.5%Carbopol-934)  were  prepared.  A1 showed  low  consistency  and  A3 
showed very high viscosity. The gel formulation A2 (1.0% carbopol-934) exhibited 
desired consistency. 
Carbopol-940 as a gelling agent
Formulations with formula B1 (0.5%Carbopol-940), B2 (1.0%Carbopol-940) 
and  B3 (1.5%Carbopol-940)  were  prepared.  B1 showed  low  consistency  and  B3 
showed very high viscosity. The gel formulation B2 (1.0% carbopol-940) exhibited 
desired consistency. 
Hydroxypropyl methyl cellulose as a gelling agent
Formulations  with  formula  C1 (1.0%HPMC),  C2 (1.5%HPMC),  C3 
(3.0%HPMC)  and  C4 (4.0%HPMC)  were  prepared.  C1 and  C2 showed  low 
consistency and C4 was highly viscous. The formulation C3 (3.0%HPMC) exhibited 
desired consistency. 
Sodium Carboxy methyl cellulose as a gelling agent
Formulations with formula D1 (2.0%SodiumCMC), D2 (3.0%SodiumCMC) 
and  D3  (4.0% SodiumCMC)  were  prepared.  D1 showed  low consistency  and  D3 
showed very high viscosity.  The gel formulation D2 (3.0%SodiumCMC) exhibited 
desired consistency. 
Evaluation of Acyclovir gels
All the optimized gel formulations were subjected to evaluation studies
Estimation of drug content
The amount and percentage of drug present in gel formulation using different 
polymers were estimated as per the procedure. The prepared gel using 1% carbopol-
934(A2) showed maximum drug content (101.72%) compared to other formulations, 
The results were shown in the Table 16.
pH Measurements
The pH measurements of all the gel formulations were carried out by using digital 
pH meter. The pH of the formulations were ranged from 6.8 to 7.2 and the results 
were shown in Table 17
Determination of viscosity
The viscosity of the gels were determined using Brookfield Viscometer. The 
viscosity of the formulations were ranged from 36,000 to 51,000cps and the results 
were shown in Table 18
Extrudability
The extrudability of the gel formulations were checked as per the procedure. 
Extrudability of carbopol and HPMC gels were excellent than sodiumCMC gel and 
the results were shown in Table 19.
Determination of Spreadability
The  spreadability  of  gels  was  determined  as  per  the  procedure.  From 
spreadability data is observed that the formulation with 1.0% carbopol-934 showed 
maximum (8cm), where as the formulations with 1%carbopol-940, 3%, HPMC and 
SodiumCMC 3% were showed significant spreadability. The results were tabulated 
in Table 20
In vitro drug release of gel formulations 
In vitro drug release of gel formulations were carried out as per the 
procedure. The percentage release of drug from different gel formulations at the end 
of 8hrs was determined.
 1.0  % carbopol-934  shows maximum release  (64.91%).  The  addition  of 
DMSO as permeation enhancer improves the drug release from gel formulation.
1.0% carbopol-940 also showed a  similar  release  pattern,  but  the  release  was 
lesser (51.47%). The addition of DMSO as permeation enhancer improves the drug 
release from gel formulation.
In case of HPMC and SodiumCMC gels the release was much lesser than 
carbopol  gels.  The addition  of  DMSO as  permeation  enhancer  drug release  was 
improved. 
Based on the drug release A2 (1.0 % carbopol-934) was the best formulation 
and the percentage release was found to be 64.91% . So, stability and In vivo studies 
were carried out for A2 formulation. 
The percentage  release  of  drug from different  gel  formulations  was shown in 
Table 21 - 29 and Figure 16 -25.
Stability studies for the formulation A2 (1.0 % carbopol-934) 
Stability study for the best formulation was done as per the procedure. The 
gel was both physically and chemically stable at 4-50c, Room temperature and 
37±50c. The results were tabulated in Table 30 & 31. 
Skin irritation test
Skin  irritation  test  was  carried  out  as  per  the  procedure,  there  was  no 
erythema and edema and any kind of reaction. Thus the gel was found to be safer for 
topical use. The observations were shown in the figure 26 & 27.
In vivo studies for the selected gel formulation
In vivo studies were carried out as per procedure. The blood samples were 
drawn  at  different  time  intervals  for  Standard  and  Test  group  of  animals  were 
analyzed for the absorbance at  255nm in UV-Spectrophotometer.  The absorbance 
values were interpreted with standard curve the plasma drug concentration and the 
pharmacokinetic parameters were determined.
The bioavailability of Acyclovir in Test and Standard were estimated by the 
measurement  of  Area  Under  Curve  (AUC)  and  the  relative  bioavailability  was 
estimated. The bioavailability of the drug in Test was more than the Standard.
The  tmax was  3hours  for  both  Test  and  Standard  and   (peak  plasma 
concentration) Cmax was found to be 24.329 and 21.962 respectively. The elimination 
rate constant (Ke) for Standard and Test was found to be 0.230 and 0.234 hour-1.
The elimination half life (t/2) for Standard and Test was found to be 3.01 and 
2.96hours. The absorption rate constant (Ka) was determined by Residual method 
was  found  to  be  0.575  and  0.621hour-1 for  Test  and  Standard  respectively.  The 
results were shown in Table 32 – 34.
SUMMARY AND CONCLUSION
The present work describes a study on “Formulation and Evaluation studies 
of Acyclovir topical gels for Antiviral activity”
Acyclovir is a broad spectrum antiviral agent against Herpes Simplex Virus 
and Varicella Zoster Virus, which is specific to viral-infected cells with low toxicity 
and  which  is  less  toxic  than  earlier  generation  of  antiviral  agents  and  as  such 
represents a major therapeutic advance.  This drug was selected for the study because 
it  has  good  percutaneous  absorption  and  appears  to  be  more  active  as  antiviral 
activity and is well  tolerated.  The polymers namely Carbopol-934, Carbopol-940, 
Hydroxypropyl methyl cellulose and Sodium carboxy methyl cellulose were used for 
formulation of gels and studied for their drug release from the gel formulations.
It  is evidence from the IR spectrum that all  the polymers  used in the gel 
formulations were compatible with the drug Acyclovir.
Different formulations of Acyclovir were prepared by using Carbopol-934, 
Carbopol-940,  Hydroxypropyl  methyl  cellulose  and  Sodium  carboxy  methyl 
cellulose  in  varying proportions.  Carbopol  gels  were transparent,  non-greasy and 
smooth on application. SodiumCMC and HPMC gels were opaque, non-greasy and 
sticking on application.
The gel  was prepared  using  1%Carbopol-934 has  maximum drug content 
(101.72%) than the others.
The pH of the formulations ranged from 6.8 to 7.2 and viscosity is from 
36,000 to 51,000cps.
Extrudability of carbopol and HPMC gels were excellent than the SodiumCMC gel.
The spreadability data shown that the formulation with 1%Carbopol- 934 has 
the highest value (8cm), where as the others have significant values.
In  vitro  release  studies  of  the  formulations  were  carried  out  across  the 
cellophane  membrane  using  a  diffusion  cell.  The  release  was  highest  for  the 
formulation A2 (1%Carbopol-934) and on the addition of DMSO as a permeation 
enhancer the drug release was improved.
The formulation B2, C3 and D2 also have significant percentage release and on 
addition of DMSO as a permeation enhancer the drug release from gel formulation 
was improved.  Hence based on the above results,  out of 13 formulations A2 was 
chosen as the best formulation.
Stability studies were carried out by placing the gels in collapsible tube at 4-
50c,  Room temperature  and 37±50C for  3  months  and also  analyzed  for  various 
physical and chemical parameters. The result indicates that the prepared gel was both 
stable physically and chemically at all storage conditions.
From the  skin  irritation  test  it  was  observed that  the  formulation  A2 was 
found to be safer for topical use.
In vivo studies  were carried out  by collecting  blood samples  from albino 
rabbits  at  regular  intervals.  The  plasma  drug  concentration  and  pharmacokinetic 
parameters  were  determined.  From  the  above  data  it  was  observed  that  the 
bioavailability of the drug in Test was higher than Standard.
From  this  investigation,  it  was  concluded  that  formulation  A2 with  1% 
Carbopol-934  may  be  the  best  formulation  having  good  in  vitro  release  profile, 
stability and bioavailability. Based on the results from the study further utility of the 
dosage form may depend on pharmacokinetic data. Forthcoming research work of 
antiviral activity may contribute in the challenging area.
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